Thomas J Kipps
#93,962
Most Influential Person Now
Researcher
Thomas J Kipps's AcademicInfluence.com Rankings
Thomas J Kippsphilosophy Degrees
Philosophy
#3518
World Rank
#5672
Historical Rank
Logic
#1205
World Rank
#1896
Historical Rank
Download Badge
Philosophy
Thomas J Kipps's Degrees
- Bachelors Biology University of California, San Diego
- Doctorate Medicine University of California, San Diego
- PhD Immunology University of California, San Diego
Similar Degrees You Can Earn
Why Is Thomas J Kipps Influential?
(Suggest an Edit or Addition)Thomas J Kipps's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia (2002) (5130)
- miR-15 and miR-16 induce apoptosis by targeting BCL2. (2005) (3655)
- Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. (2008) (3147)
- A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. (2005) (2499)
- Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. (2014) (1570)
- Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. (2016) (1405)
- Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. (2014) (1363)
- MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. (2004) (1350)
- Relation of Gene Expression Phenotype to Immunoglobulin Mutation Genotype in B Cell Chronic Lymphocytic Leukemia (2001) (1215)
- Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. (2015) (1185)
- CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. (2006) (1185)
- ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. (2004) (973)
- iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. (2018) (874)
- Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. (2000) (774)
- MiR-15a and miR-16-1 cluster functions in human leukemia (2008) (763)
- Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. (2012) (753)
- Ultraconserved regions encoding ncRNAs are altered in human leukemias and carcinomas. (2007) (734)
- Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal (1993) (657)
- Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. (2010) (596)
- Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia. (2002) (578)
- Clinical utility of microarray-based gene expression profiling in the diagnosis and subclassification of leukemia: report from the International Microarray Innovations in Leukemia Study Group. (2010) (566)
- Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia (2018) (564)
- Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma. (2017) (520)
- Tcl1 expression in chronic lymphocytic leukemia is regulated by miR-29 and miR-181. (2006) (486)
- Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions. (2019) (480)
- Activation of the Wnt signaling pathway in chronic lymphocytic leukemia. (2004) (427)
- Downregulation of Death-Associated Protein Kinase 1 (DAPK1) in Chronic Lymphocytic Leukemia (2007) (391)
- Reprogramming of miRNA networks in cancer and leukemia. (2010) (374)
- CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia. (2000) (367)
- Salinomycin inhibits Wnt signaling and selectively induces apoptosis in chronic lymphocytic leukemia cells (2011) (348)
- Nurselike cells express BAFF and APRIL, which can promote survival of chronic lymphocytic leukemia cells via a paracrine pathway distinct from that of SDF-1alpha. (2005) (335)
- Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. (2008) (322)
- Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a (2008) (312)
- Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells. (2005) (304)
- ATM Mutations in Cancer: Therapeutic Implications (2016) (304)
- Immunoglobulin VH3 gene products: natural ligands for HIV gp120. (1993) (284)
- Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia. (2011) (280)
- ZAP-70 directly enhances IgM signaling in chronic lymphocytic leukemia. (2005) (273)
- Functional expression of CXCR4 (CD184) on small-cell lung cancer cells mediates migration, integrin activation, and adhesion to stromal cells (2003) (273)
- Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy. (2014) (272)
- Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study. (2017) (268)
- Chronic lymphocytic leukemia B cells of more than 1% of patients express virtually identical immunoglobulins. (2004) (267)
- Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study (2019) (266)
- Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia. (2009) (265)
- Distinctive features of "nurselike" cells that differentiate in the context of chronic lymphocytic leukemia. (2002) (265)
- Protection of CLL B cells by a follicular dendritic cell line is dependent on induction of Mcl-1. (2002) (262)
- ATM mutations in B-cell chronic lymphocytic leukemia. (1999) (260)
- Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity. (2016) (260)
- Gene transfer of CD40-ligand induces autologous immune recognition of chronic lymphocytic leukemia B cells. (1998) (260)
- Importance of immunoglobulin isotype in human antibody-dependent, cell- mediated cytotoxicity directed by murine monoclonal antibodies (1985) (254)
- Developmentally restricted immunoglobulin heavy chain variable region gene expressed at high frequency in chronic lymphocytic leukemia. (1989) (254)
- Ig VH1 genes expressed in B cell chronic lymphocytic leukemia exhibit distinctive molecular features. (1997) (245)
- The CD5 B cell. (1989) (243)
- BAFF and APRIL support chronic lymphocytic leukemia B-cell survival through activation of the canonical NF-kappaB pathway. (2007) (241)
- DNA methylation dynamics during B cell maturation underlie a continuum of disease phenotypes in chronic lymphocytic leukemia (2016) (237)
- Final analysis from RESONATE: Up to six years of follow‐up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma (2019) (236)
- Acquired CD40-ligand deficiency in chronic lymphocytic leukemia (1997) (227)
- Fibroblast-Like Synoviocytes of Mesenchymal Origin Express Functional B Cell-Activating Factor of the TNF Family in Response to Proinflammatory Cytokines1 (2005) (224)
- microRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survival. (2010) (224)
- Autoantibodies in chronic lymphocytic leukemia and related systemic autoimmune diseases. (1993) (222)
- A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia. (2015) (220)
- ROR1 Is Expressed in Human Breast Cancer and Associated with Enhanced Tumor-Cell Growth (2012) (218)
- NOTCH1 mutations in CLL associated with trisomy 12. (2012) (216)
- The soluble CD40 ligand sCD154 in systemic lupus erythematosus. (1999) (212)
- Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study. (2019) (206)
- Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL (2017) (205)
- Karyotype-specific microRNA signature in chronic lymphocytic leukemia. (2009) (202)
- Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia. (2013) (201)
- Systemic immunological effects of cytokine genes injected into skeletal muscle. (1993) (190)
- Chronic lymphocytic leukaemia (2017) (187)
- The triterpenoid CDDO induces apoptosis in refractory CLL B cells. (2002) (187)
- Perspectives on the use of new diagnostic tools in the treatment of chronic lymphocytic leukemia. (2005) (183)
- Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials (2017) (182)
- Relationship of deoxycytidine kinase and cytoplasmic 5'-nucleotidase to the chemotherapeutic efficacy of 2-chlorodeoxyadenosine. (1993) (181)
- Transcriptome Sequencing Reveals Potential Mechanism of Cryptic 3’ Splice Site Selection in SF3B1-mutated Cancers (2015) (181)
- A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study (2015) (180)
- Functional properties of a unique subset of cytotoxic CD3+ T lymphocytes that express Fc receptors for IgG (CD16/Leu-11 antigen) (1985) (179)
- Chemokine Receptors and Stromal Cells in the Homing and Homeostasis of Chronic Lymphocytic Leukemia B Cells (2002) (177)
- Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia. (2012) (177)
- Autoantibody-associated kappa light chain variable region gene expressed in chronic lymphocytic leukemia with little or no somatic mutation. Implications for etiology and immunotherapy (1988) (177)
- Preferential linkage of bcl-2 to immunoglobulin light chain gene in chronic lymphocytic leukemia (1990) (176)
- Fibroblast-like synoviocytes support B-cell pseudoemperipolesis via a stromal cell-derived factor-1- and CD106 (VCAM-1)-dependent mechanism. (2001) (176)
- The onco-embryonic antigen ROR1 is expressed by a variety of human cancers. (2012) (171)
- Expression of CD27 and its ligand, CD70, on chronic lymphocytic leukemia B cells. (1995) (164)
- Rheumatoid factor and immune networks. (1987) (162)
- TNFR-Associated Factor Family Protein Expression in Normal Tissues and Lymphoid Malignancies (2000) (162)
- Dysregulation of a family of short noncoding RNAs, tsRNAs, in human cancer (2016) (162)
- Chronic lymphocytic leukemia modeled in mouse by targeted miR-29 expression (2010) (162)
- Oral antilymphocyte activity and induction of apoptosis by 2-chloro-2'-arabino-fluoro-2'-deoxyadenosine. (1992) (158)
- Functional properties and effect on growth suppression of human neuroblastoma tumors by isotype switch variants of monoclonal antiganglioside GD2 antibody 14.18. (1989) (158)
- MicroRNA-155 influences B-cell receptor signaling and associates with aggressive disease in chronic lymphocytic leukemia. (2014) (158)
- Characterization of the 13q14 tumor suppressor locus in CLL: identification of ALT1, an alternative splice variant of the LEU2 gene. (2001) (156)
- An international standardization programme towards the application of gene expression profiling in routine leukaemia diagnostics: the Microarray Innovations in LEukemia study prephase (2008) (156)
- Ovarian cancer stem cells express ROR1, which can be targeted for anti–cancer-stem-cell therapy (2014) (156)
- Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia. (2019) (150)
- Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab. (2019) (148)
- Wnt5a induces ROR1/ROR2 heterooligomerization to enhance leukemia chemotaxis and proliferation. (2015) (148)
- Transcriptomic Characterization of SF3B1 Mutation Reveals Its Pleiotropic Effects in Chronic Lymphocytic Leukemia. (2016) (147)
- ZAP-70 enhances IgM signaling independent of its kinase activity in chronic lymphocytic leukemia. (2008) (146)
- Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia. (2008) (144)
- Transforming growth factor beta as endogenous growth inhibitor of chronic lymphocytic leukemia B cells (1994) (144)
- Evidence for somatic selection of natural autoantibodies (1992) (143)
- Shared idiotypic determinants on antibodies and T-cell-derived suppressor factor specific for the random terpolymer L-glutamic acid60- L-alanine30-L-tyrosine10 (1979) (141)
- Rational Design and Real Time, In-Cell Detection of the Proapoptotic Activity of a Novel Compound Targeting Bcl-XL (2004) (141)
- A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia (2015) (140)
- Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial. (2020) (139)
- In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. (2015) (139)
- ZAP-70 is a novel conditional heat shock protein 90 (Hsp90) client: inhibition of Hsp90 leads to ZAP-70 degradation, apoptosis, and impaired signaling in chronic lymphocytic leukemia. (2005) (138)
- Evolution of DNA methylation is linked to genetic aberrations in chronic lymphocytic leukemia. (2014) (138)
- Targeting ROR1 inhibits epithelial-mesenchymal transition and metastasis. (2013) (136)
- New roles for rheumatoid factor. (1991) (135)
- miR-181b is a biomarker of disease progression in chronic lymphocytic leukemia. (2011) (128)
- Structure-function studies on a polyreactive (natural) autoantibody. Polyreactivity is dependent on somatically generated sequences in the third complementarity-determining region of the antibody heavy chain. (1994) (126)
- miR-150 influences B-cell receptor signaling in chronic lymphocytic leukemia by regulating expression of GAB1 and FOXP1. (2014) (125)
- CCL3 (MIP-1α) plasma levels and the risk for disease progression in chronic lymphocytic leukemia. (2011) (124)
- Rituximab in combination with high-dose methylprednisolone for the treatment of fludarabine refractory high-risk chronic lymphocytic leukemia (2008) (122)
- Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia. (2011) (120)
- Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables. (2019) (120)
- DNA vaccines encoding full-length or truncated Neu induce protective immunity against Neu-expressing mammary tumors. (1998) (116)
- Immunostimulatory effects of a plasmid expressing CD40 ligand (CD154) on gene immunization. (1997) (114)
- Venetoclax and obinutuzumab in chronic lymphocytic leukemia. (2017) (113)
- Tcl1 functions as a transcriptional regulator and is directly involved in the pathogenesis of CLL (2008) (113)
- Quantitative DNA methylation analysis identifies a single CpG dinucleotide important for ZAP-70 expression and predictive of prognosis in chronic lymphocytic leukemia. (2012) (112)
- Phase I study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemia (2012) (111)
- Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia. (2010) (109)
- Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study (2020) (108)
- TWIST2 demonstrates differential methylation in immunoglobulin variable heavy chain mutated and unmutated chronic lymphocytic leukemia. (2005) (108)
- Phase 1 Study of Lumiliximab with Detailed Pharmacokinetic and Pharmacodynamic Measurements in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (2007) (108)
- Familial cancer associated with a polymorphism in ARLTS1. (2005) (107)
- RITUXIMAB IN COMBINATION WITH HIGH DOSE METHYLPREDNISOLONE FOR THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (2009) (106)
- Lack of Allelic Exclusion in B Cell Chronic Lymphocytic Leukemia (1997) (105)
- Deoxyribonucleic acid vaccines encoding antigens with rapid proteasome-dependent degradation are highly efficient inducers of cytolytic T lymphocytes. (1997) (105)
- Latent sensitivity to Fas-mediated apoptosis after CD40 ligation may explain activity of CD154 gene therapy in chronic lymphocytic leukemia (2002) (105)
- 13q14 deletions in CLL involve cooperating tumor suppressors. (2010) (104)
- Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2 (2018) (102)
- Chronic lymphocytic leukemia cells display p53-dependent drug-induced Puma upregulation (2005) (102)
- Cloning and characterization of CLLD6, CLLD7, and CLLD8, novel candidate genes for leukemogenesis at chromosome 13q14, a region commonly deleted in B-cell chronic lymphocytic leukemia. (2001) (102)
- The down-regulation of miR-125b in chronic lymphocytic leukemias leads to metabolic adaptation of cells to a transformed state. (2012) (101)
- Phase I Trial: Cirmtuzumab Inhibits ROR1 Signaling and Stemness Signatures in Patients with Chronic Lymphocytic Leukemia. (2018) (101)
- Pre-clinical Specificity and Safety of UC-961, a First-In-Class Monoclonal Antibody Targeting ROR1. (2015) (99)
- Flavopiridol administered as a 24-hour continuous infusion in chronic lymphocytic leukemia lacks clinical activity. (2005) (99)
- Increased expression of CD152 (CTLA-4) by normal T lymphocytes in untreated patients with B-cell chronic lymphocytic leukemia (2005) (97)
- Genetic influence on the levels of circulating CD5 B lymphocytes. (1987) (96)
- Management guidelines for use of alemtuzumab in B-cell chronic lymphocytic leukemia. (2004) (95)
- High-level ROR1 associates with accelerated disease progression in chronic lymphocytic leukemia. (2016) (93)
- Relevance of the immunoglobulin VH somatic mutation status in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab (FCR) or related chemoimmunotherapy regimens. (2009) (91)
- Second Interim Analysis of a Phase 3 Study of Idelalisib (ZYDELIG®) Plus Rituximab (R) for Relapsed Chronic Lymphocytic Leukemia (CLL): Efficacy Analysis in Patient Subpopulations with Del(17p) and Other Adverse Prognostic Factors (2014) (91)
- Isolation and characterization of a light chain variable region gene for human rheumatoid factors (1987) (91)
- High-frequency expression of a conserved kappa light-chain variable-region gene in chronic lymphocytic leukemia. (1987) (91)
- Cyclic nucleotide phosphodiesterase profiling reveals increased expression of phosphodiesterase 7B in chronic lymphocytic leukemia (2008) (90)
- Ethacrynic Acid Exhibits Selective Toxicity to Chronic Lymphocytic Leukemia Cells by Inhibition of the Wnt/β-Catenin Pathway (2009) (90)
- Tumor necrosis factor-alpha facilitates induction of CD80 (B7-1) and CD54 on human B cells by activated T cells: complex regulation by IL-4, IL-10, and CD40L. (1995) (89)
- Relationship of the CD5 B cell to human tonsillar lymphocytes that express autoantibody-associated cross-reactive idiotypes. (1991) (88)
- Inhibition of chemotherapy resistant breast cancer stem cells by a ROR1 specific antibody (2019) (86)
- Bcl-2 Inhibitor ABT-199 (GDC-0199) Monotherapy Shows Anti-Tumor Activity Including Complete Remissions In High-Risk Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL) (2013) (83)
- A high-density SNP genome-wide linkage search of 206 families identifies susceptibility loci for chronic lymphocytic leukemia. (2007) (83)
- Expression of the immunoglobulin VH gene 51p1 is proportional to its germline gene copy number. (1996) (82)
- ROR1 can interact with TCL1 and enhance leukemogenesis in Eµ-TCL1 transgenic mice (2013) (81)
- A Phase 1 Study of Venetoclax (ABT-199 / GDC-0199) Monotherapy in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma (2015) (81)
- B-cell activating factor and v-Myc myelocytomatosis viral oncogene homolog (c-Myc) influence progression of chronic lymphocytic leukemia (2010) (81)
- Tumor suppression by phospholipase C-beta3 via SHP-1-mediated dephosphorylation of Stat5. (2009) (80)
- Use of IGHV3-21 in chronic lymphocytic leukemia is associated with high-risk disease and reflects antigen-driven, post-germinal center leukemogenic selection. (2008) (79)
- Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies. (2019) (78)
- Lenalidomide inhibits the proliferation of CLL cells via a cereblon/p21(WAF1/Cip1)-dependent mechanism independent of functional p53. (2014) (78)
- Targeting chronic lymphocytic leukemia cells with a humanized monoclonal antibody specific for CD44 (2013) (78)
- Chronic lymphocytic leukemia (1998) (77)
- Non-codingRNA sequence variations in human chronic lymphocytic leukemia and colorectal cancer. (2010) (76)
- ROR1 is expressed on hematogones (non-neoplastic human B-lymphocyte precursors) and a minority of precursor-B acute lymphoblastic leukemia. (2011) (76)
- Normal B Cells Express 51p1-Encoded Ig Heavy Chains That Are Distinct From Those Expressed by Chronic Lymphocytic Leukemia B Cells1 (2001) (75)
- Inhibitors of XIAP sensitize CD40-activated chronic lymphocytic leukemia cells to CD95-mediated apoptosis. (2005) (75)
- Heterogeneity among Epstein-Barr virus-seropositive donors in the generation of immunoblastic B-cell lymphomas in SCID mice receiving human peripheral blood leukocyte grafts. (1992) (75)
- Free circulating soluble CD52 as a tumor marker in chronic lymphocytic leukemia and its implication in therapy with anti‐CD52 antibodies (2004) (75)
- Subnetwork-based analysis of chronic lymphocytic leukemia identifies pathways that associate with disease progression. (2011) (74)
- Elevated expression of CD80 (B7/BB1) and other accessory molecules on synovial fluid mononuclear cell subsets in rheumatoid arthritis. (1994) (73)
- Targeting the spliceosome in chronic lymphocytic leukemia with the macrolides FD-895 and pladienolide-B (2015) (73)
- Ibrutinib inhibits CD20 upregulation on CLL B cells mediated by the CXCR4/SDF-1 axis. (2016) (73)
- Chronic lymphocytic leukaemia (2017) (72)
- Upregulation of long noncoding RNA MIAT in aggressive form of chronic lymphocytic leukemias (2016) (72)
- Common clonal origin of chronic lymphocytic leukemia and high-grade lymphoma of Richter's syndrome. (1993) (72)
- Elucidating the CXCL12/CXCR4 Signaling Network in Chronic Lymphocytic Leukemia through Phosphoproteomics Analysis (2010) (71)
- The Dohner fluorescence in situ hybridization prognostic classification of chronic lymphocytic leukaemia (CLL): the CLL Research Consortium experience (2016) (71)
- Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 4.2020, NCCN Clinical Practice Guidelines in Oncology. (2020) (71)
- Phase I-II clinical trial of oxaliplatin, fludarabine, cytarabine, and rituximab therapy in aggressive relapsed/refractory chronic lymphocytic leukemia or Richter syndrome. (2013) (70)
- MicroRNAs in the pathogeny of chronic lymphocytic leukaemia (2007) (70)
- Trisomy 12 chronic lymphocytic leukemia cells exhibit upregulation of integrin signaling that is modulated by NOTCH1 mutations. (2014) (70)
- Randomized phase 2 study of obinutuzumab monotherapy in symptomatic, previously untreated chronic lymphocytic leukemia. (2016) (70)
- Ulocuplumab (BMS-936564 / MDX1338): a fully human anti-CXCR4 antibody induces cell death in chronic lymphocytic leukemia mediated through a reactive oxygen species-dependent pathway (2015) (70)
- Uniform high frequency expression of autoantibody-associated crossreactive idiotypes in the primary B cell follicles of human fetal spleen (1990) (69)
- Chronic lymphocytic leukemia (1997) (69)
- Obinutuzumab plus fludarabine/cyclophosphamide or bendamustine in the initial therapy of CLL patients: the phase 1b GALTON trial. (2015) (69)
- Erratum: miR-15 and miR-16 induce apoptosis by targeting BCL2 (Proceedings of the National Academy of Sciences of the United States of America (September 27, 2005) 102, 39 (13944-13949) DOI: 10.1073/pnas.0506654102) (2006) (69)
- Function of B cells expressing a human immunoglobulin M rheumatoid factor autoantibody in transgenic mice (1993) (69)
- Chronic lymphocytic leukemia cells receive RAF-dependent survival signals in response to CXCL12 that are sensitive to inhibition by sorafenib. (2011) (68)
- Growth dynamics in naturally progressing chronic lymphocytic leukaemia (2019) (67)
- Molecular characterization of a major autoantibody-associated cross-reactive idiotype in Sjogren's syndrome. (1989) (66)
- Lenalidomide and rituximab for the initial treatment of patients with chronic lymphocytic leukemia: a multicenter clinical-translational study from the chronic lymphocytic leukemia research consortium. (2014) (66)
- Validation of ZAP-70 methylation and its relative significance in predicting outcome in chronic lymphocytic leukemia. (2014) (66)
- Cirmtuzumab inhibits Wnt5a-induced Rac1 activation in chronic lymphocytic leukemia treated with ibrutinib (2016) (66)
- Intraclonal diversity in the VH genes expressed by CD5- chronic lymphocytic leukemia-producing pathologic IgM rheumatoid factor. (1990) (65)
- Deficient Fas ligand expression by synovial lymphocytes from patients with rheumatoid arthritis. (1997) (64)
- Commonly Occurring Cell Subsets in High-Grade Serous Ovarian Tumors Identified by Single-Cell Mass Cytometry (2018) (64)
- Characterization of four homologous L chain variable region genes that are related to 6B6.6 idiotype positive human rheumatoid factor L chains. (1989) (63)
- Fas-ligand (CD178) and TRAIL synergistically induce apoptosis of CD40-activated chronic lymphocytic leukemia B cells. (2005) (63)
- AGS67E, an Anti-CD37 Monomethyl Auristatin E Antibody–Drug Conjugate as a Potential Therapeutic for B/T-Cell Malignancies and AML: A New Role for CD37 in AML (2015) (63)
- Rational design and real time, in-cell detection of the proapoptotic activity of a novel compound targeting Bcl-X(L). (2004) (63)
- Idiotypic analysis of anti-GAT antibodies. I. Presence of common idiotypic specificities in both responder and nonresponder mice. (1978) (63)
- Phase I study of single-agent CC-292, a highly selective Bruton’s tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia (2016) (62)
- Dielectrophoretic isolation and detection of cfc‐DNA nanoparticulate biomarkers and virus from blood (2013) (62)
- Recombinant antibodies encoded by IGHV1-69 react with pUL32, a phosphoprotein of cytomegalovirus and B-cell superantigen. (2012) (62)
- Characterization of two immunoglobulin VH genes that are homologous to human rheumatoid factors. (1989) (62)
- MicroRNAs and B cell receptor signaling in chronic lymphocytic leukemia (2013) (61)
- Autoantibody-associated cross-reactive idiotypes expressed at high frequency in chronic lymphocytic leukemia relative to B-cell lymphomas of follicular center cell origin. (1988) (61)
- Ig V region gene expression in small lymphocytic lymphoma with little or no somatic hypermutation. (1989) (60)
- Tcl1 protein functions as an inhibitor of de novo DNA methylation in B-cell chronic lymphocytic leukemia (CLL) (2012) (60)
- TCL1 targeting miR-3676 is codeleted with tumor protein p53 in chronic lymphocytic leukemia (2015) (59)
- CD154 induces p73 to overcome the resistance to apoptosis of chronic lymphocytic leukemia cells lacking functional p53. (2006) (59)
- An anti‐B cell autoantibody from Wiskott‐Aldrich syndrome which recognizes i blood group specificity on normal human B cells (1992) (59)
- Isolation and characterization of human VkIII germ-line genes. Implications for the molecular basis of human VkIII light chain diversity. (1987) (58)
- A phase I study of immune gene therapy for patients with CLL using a membrane-stable, humanized CD154 (2010) (57)
- Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single‐agent ibrutinib (2017) (57)
- A phase II study of the selective phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor idelalisib (GS-1101) in combination with rituximab (R) in treatment-naive patients (pts) ≥65 years with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). (2013) (56)
- Soluble CD154 in rheumatoid arthritis: elevated plasma levels in cases with vasculitis. (2001) (56)
- The pathogenesis of chronic lymphocytic leukemia. (2014) (56)
- EGR2 mutations define a new clinically aggressive subgroup of chronic lymphocytic leukemia (2017) (56)
- NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2019. (2017) (55)
- A Murine Model of Chronic Lymphocytic Leukemia Based on B Cell-Restricted Expression of Sf3b1 Mutation and Atm Deletion. (2019) (55)
- Preliminary Results From A Phase I Dose Escalation Study to Determine the Maximum Tolerated Dose of Plerixafor In Combination with Rituximab In Patients with Relapsed Chronic Lymphocytic Leukemia (2010) (55)
- Elevation of soluble CD307 (IRTA2/FcRH5) protein in the blood and expression on malignant cells of patients with multiple myeloma, chronic lymphocytic leukemia, and mantle cell lymphoma (2007) (55)
- Nonstochastic pairing of immunoglobulin heavy and light chains expressed by chronic lymphocytic leukemia B cells is predicated on the heavy chain CDR3. (2005) (54)
- ABT-199 (GDC-0199) in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL): High complete- response rate and durable disease control. (2014) (54)
- Chronic lymphocytic leukemia of Emu-TCL1 transgenic mice undergoes rapid cell turnover that can be offset by extrinsic CD257 to accelerate disease progression. (2009) (54)
- IRF4 mutations in chronic lymphocytic leukemia. (2011) (54)
- Lack of extensive mutations in the VH5 genes used in common B cell chronic lymphocytic leukemia (1993) (54)
- Somatic MED12 mutations are associated with poor prognosis markers in chronic lymphocytic leukemia (2014) (53)
- Ofatumumab (HuMax-CD20), a Novel CD20 Monoclonal Antibody, Is An Active Treatment for Patients with CLL Refractory to Both Fludarabine and Alemtuzumab or Bulky Fludarabine-Refractory Disease: Results from the Planned Interim Analysis of An International Pivotal Trial (2008) (52)
- Biology and treatment of chronic lymphocytic leukemia. (2003) (52)
- Novel immune-based treatment strategies for chronic lymphocytic leukemia. (2005) (52)
- Phase I First-inHuman Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (2017) (51)
- Dielectrophoretic isolation and detection of cancer‐related circulating cell‐free DNA biomarkers from blood and plasma (2014) (51)
- Sleeping Beauty Transposition of Chimeric Antigen Receptors Targeting Receptor Tyrosine Kinase-Like Orphan Receptor-1 (ROR1) into Diverse Memory T-Cell Populations (2015) (51)
- Studies of HIV infection and the development of Epstein-Barr virus-related B cell lymphomas following transfer of human lymphocytes to mice with severe combined immunodeficiency. (1989) (51)
- Determination of Recommended Phase 2 Dose of ABT-199 (GDC-0199) Combined with Rituximab (R) in Patients with Relapsed / Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) (2014) (51)
- Induction of antibodies to a kappa V region by gene immunization. (1993) (51)
- Wnt5a Signaling in Normal and Cancer Stem Cells (2017) (50)
- Cytotoxicity, apoptosis, and viral replication in tumor cells treated with oncolytic ribonucleotide reductase-defective herpes simplex type 1 virus (hrR3) combined with ionizing radiation (2000) (50)
- Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study (2021) (50)
- The B-cell receptor and ZAP-70 in chronic lymphocytic leukemia. (2007) (49)
- The V4-34 encoded anti-i autoantibodies recognize a large subset of human and mouse B-cells. (1996) (49)
- Final results of EFC6663: a multicenter, international, phase 2 study of alvocidib for patients with fludarabine-refractory chronic lymphocytic leukemia. (2015) (49)
- CD5-positive B-cell malignancies frequently express cross-reactive idiotypes associated with IgM autoantibodies. (1990) (49)
- Efficient infection of a human T-cell line and of human primary peripheral blood leukocytes with a pseudotyped retrovirus vector. (1996) (49)
- Stimulation of chronic lymphocytic leukemia cells with CpG oligodeoxynucleotide gives consistent karyotypic results among laboratories: a CLL Research Consortium (CRC) Study. (2010) (49)
- Rapid electrokinetic isolation of cancer-related circulating cell-free DNA directly from blood. (2014) (48)
- Deep and Durable Responses Following Venetoclax (ABT-199 / GDC-0199) Combined with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Results from a Phase 1b Study (2015) (48)
- Sorafenib-Induced Apoptosis of Chronic Lymphocytic Leukemia Cells Is Associated with Downregulation of RAF and Myeloid Cell Leukemia Sequence 1 (Mcl-1) (2012) (48)
- Phase 1 Study Of Single Agent CC-292, a Highly Selective Bruton's Tyrosine Kinase (BTK) Inhibitor, In Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) (2013) (47)
- Tcl1 interacts with Atm and enhances NF-κB activation in hematologic malignancies. (2012) (46)
- Ofatumumab Combined with Fludarabine and Cyclophosphamide (O-FC) Shows High Activity in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL): Results From a Randomized, Multicenter, International, Two-Dose, Parallel Group, Phase II Trial. (2009) (46)
- Updated Efficacy and Safety from the Phase 3 Resonate-2 Study: Ibrutinib As First-Line Treatment Option in Patients 65 Years and Older with Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia (2016) (45)
- Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia. (2019) (45)
- Wnt5a induces ROR1 to complex with HS1 to enhance migration of chronic lymphocytic leukemia cells (2017) (44)
- Transfer of human chronic lymphocytic leukemia to mice with severe combined immune deficiency. (1992) (43)
- Immunoglobulin genes in chronic lymphocytic leukemia. (1993) (43)
- Real‐world clinical experience in the Connect® chronic lymphocytic leukaemia registry: a prospective cohort study of 1494 patients across 199 US centres (2016) (42)
- Immunoglobulin V Gene Expression in CD5 B‐Cell Malignancies a (1992) (42)
- EBV-associated B-cell lymphomas following transfer of human peripheral blood lymphocytes to mice with severe combined immune deficiency. (1990) (42)
- Inhibitors of B-cell receptor signaling for patients with B-cell malignancies. (2012) (42)
- Five-Year Analysis of Murano Study Demonstrates Enduring Undetectable Minimal Residual Disease (uMRD) in a Subset of Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Patients (Pts) Following Fixed-Duration Venetoclax-Rituximab (VenR) Therapy (Tx) (2020) (41)
- Structure and function of the hematopoietic cancer niche: focus on chronic lymphocytic leukemia. (2012) (41)
- Biochemical genetic analysis of indanocine resistance in human leukemia. (2001) (41)
- Gene immunotherapy of chronic lymphocytic leukemia: a phase I study of intranodally injected adenovirus expressing a chimeric CD154 molecule. (2012) (41)
- Importance of immunoglobulin isotype in therapy of experimental autoimmune encephalomyelitis with monoclonal anti-CD4 antibody. (1987) (41)
- Immunoglobulin transcript sequence and somatic hypermutation computation from unselected RNA-seq reads in chronic lymphocytic leukemia (2015) (40)
- Further studies on the epitopes of HLA-B7 defined by murine monoclonal antibodies. (1986) (40)
- AT-101, a small molecule Bcl-2 antagonist, in treatment naïve CLL patients (pts) with high risk features; Preliminary results from an ongoing phase I trial. (2006) (40)
- Comparison of Results from a Phase 1/2 Study of Lumiliximab (Anti-CD23) in Combination with FCR for Patients with Relapsed CLL with Published FCR Results. (2006) (40)
- Epstein–Barr Virus MicroRNAs are Expressed in Patients with Chronic Lymphocytic Leukemia and Correlate with Overall Survival☆ (2015) (40)
- Dysregulation of different classes of tRNA fragments in chronic lymphocytic leukemia (2019) (39)
- Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): 1-Year Disease-Free Survival (DFS) Results From the MRD Cohort of the Phase 2 CAPTIVATE Study (2020) (39)
- Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL. (2021) (39)
- Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Results from the MRD Cohort of the Phase 2 CAPTIVATE Study. (2019) (38)
- Quaking and miR-155 interactions in inflammation and leukemogenesis (2015) (37)
- Progressive but previously untreated CLL patients with greater array CGH complexity exhibit a less durable response to chemoimmunotherapy. (2010) (37)
- Targeting the CXCR4 pathway using a novel anti-CXCR4 IgG1 antibody (PF-06747143) in chronic lymphocytic leukemia (2017) (37)
- MicroRNA dysregulation to identify therapeutic target combinations for chronic lymphocytic leukemia (2017) (37)
- Wnt5a induces ROR1 to recruit DOCK2 to activate Rac1/2 in chronic lymphocytic leukemia. (2018) (36)
- Update on a Phase 2 Study of Idelalisib in Combination with Rituximab in Treatment-Naïve Patients ≥65 Years with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) (2014) (35)
- Selection of oligonucleotide aptamers with enhanced uptake and activation of human leukemia B cells. (2003) (35)
- Reduction in mitochondrial membrane potential is an early event in Fas-independent CTL-mediated apoptosis. (1999) (35)
- Updated results of a phase I first-in-human study of the BCL-2 inhibitor ABT-199 (GDC-0199) in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). (2013) (35)
- Phase Ib trial of AVL-292, a covalent inhibitor of Bruton's tyrosine kinase (Btk), in chronic lymphocytic leukemia (CLL) and B-non-Hodgkin lymphoma (B-NHL). (2012) (35)
- CpG oligodeoxynucleotides enhance the capacity of adenovirus-mediated CD154 gene transfer to generate effective B-cell lymphoma vaccines. (2003) (35)
- Cellular immune therapy for chronic lymphocytic leukemia. (2007) (35)
- EBV-induced human B cell lymphomas in hu-PBL-SCID mice. (1992) (34)
- Isolation of heavy chain class switch variants of a monoclonal anti-DC1 hybridoma cell line: effective conversion of noncytotoxic IgG1 antibodies to cytotoxic IgG2 antibodies. (1983) (34)
- Identification of a promoter element that regulates tissue-specific expression of the human CD80 (B7.1) gene. (1996) (34)
- Molecular characterization of a supratypic cross-reactive idiotype associated with IgM autoantibodies. (1991) (34)
- Metalloprotease inhibitors block release of soluble CD27 and enhance the immune stimulatory activity of chronic lymphocytic leukemia cells. (2007) (34)
- The Philadelphia (Ph) chromosome in leukemia. II. Variant Ph translocations in acute lymphoblastic leukemia. (1985) (34)
- CD40 activation does not protect chronic lymphocytic leukemia B cells from apoptosis induced by cytotoxic T lymphocytes. (2000) (33)
- Ibrutinib restores immune cell numbers and function in first-line and relapsed/refractory chronic lymphocytic leukemia. (2020) (33)
- Venetoclax Plus Rituximab Is Superior to Bendamustine Plus Rituximab in Patients with Relapsed/ Refractory Chronic Lymphocytic Leukemia - Results from Pre-Planned Interim Analysis of the Randomized Phase 3 Murano Study (2017) (33)
- Relative seroprevalence of human herpes viruses in patients with chronic lymphocytic leukaemia (2009) (33)
- Chronic lymphocytic leukemia B cells are highly sensitive to infection by herpes simplex virus-1 via herpesvirus-entry-mediator A (2000) (33)
- A Phase 2 Study of Idelalisib Monotherapy in Previously Untreated Patients ≥65 Years with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) (2014) (32)
- Idiotypic and genetic studies of human rheumatoid factors. (1987) (32)
- An Ongoing Phase 1 Study of ABT-263; Pharmacokinetics, Safety and Anti-Tumor Activity in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) (2008) (32)
- Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia. (2019) (31)
- Homologous chromosome recombination generating immunoglobulin allotype and isotype switch variants. (1986) (31)
- Updated Efficacy Including Genetic and Clinical Subgroup Analysis and Overall Safety in the Phase 3 RESONATETM Trial of Ibrutinib Versus Ofatumumab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (2014) (31)
- Navitoclax (ABT-263) Plus Fludarabine/Cyclophosphamide/Rituximab (FCR) or Bendamustine/Rituximab (BR): A Phase 1 Study In Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) (2010) (31)
- Genetic and epigenetic profiling of CLL disease progression reveals limited somatic evolution and suggests a relationship to memory-cell development (2015) (31)
- Autoantibody-encoding kappa L chain genes frequently rearranged in lambda L chain-expressing chronic lymphocytic leukemia. (1991) (30)
- A Phase II, Open Label Study of AT-101 in Combination with Rituximab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia. Evaluation of Two Dose Regimens. (2007) (30)
- hBfl-1/hNOXA Interaction Studies Provide New Insights on the Role of Bfl-1 in Cancer Cell Resistance and for the Design of Novel Anticancer Agents (2016) (30)
- Phase 2 CAPTIVATE results of ibrutinib (ibr) plus venetoclax (ven) in first-line chronic lymphocytic leukemia (CLL). (2018) (30)
- Analysis of Immunoglobulin VH Gene Repertoire by an Anchored PCR‐Elisa a (1995) (30)
- Biased estimates of clonal evolution and subclonal heterogeneity can arise from PCR duplicates in deep sequencing experiments (2014) (29)
- Safety and Efficacy of a Combination of Venetoclax (GDC-0199/ABT-199) and Obinutuzumab in Patients with Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia - Results from a Phase 1b Study (GP28331) (2015) (29)
- Anti‐B cell autoantibodies encoded by VH 4–21 genes in human fetal spleen do not require in vivo somatic selection (1994) (29)
- Favored use of immunoglobulin V(H)4 Genes in AIDS-associated B-cell lymphoma. (1996) (29)
- Cirmtuzumab Blocks Wnt5a/ROR1-Stimulation Of NF-κB To Repress Autocrine STAT3-Activation In Chronic Lymphocytic Leukemia. (2019) (29)
- Immunobiology of chronic lymphocytic leukemia. (2003) (29)
- Updated Follow-up of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated with Lisocabtagene Maraleucel in the Phase 1 Monotherapy Cohort of Transcend CLL 004, Including High-Risk and Ibrutinib-Treated Patients (2020) (29)
- Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort. (2022) (28)
- Stabilized cyclopropane analogs of the splicing inhibitor FD-895. (2013) (28)
- Phase II study of acalabrutinib in ibrutinibintolerant patients with relapsed/refractory chronic lymphocytic leukemia (2021) (28)
- Splicing modulation sensitizes chronic lymphocytic leukemia cells to venetoclax by remodeling mitochondrial apoptotic dependencies. (2018) (28)
- Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia (2022) (28)
- Computational identification of CDR3 sequence archetypes among immunoglobulin sequences in chronic lymphocytic leukemia. (2009) (27)
- miR-29 Modulates CD40 Signaling in Chronic Lymphocytic Leukemia by Targeting TRAF4: an Axis Affected by BCR inhibitors. (2020) (27)
- Limitations of in vivo IL-12 supplementation strategies to induce Th1 early life responses to model viral and bacterial vaccine antigens. (2000) (26)
- Wnt5a causes ROR1 to complex and activate cortactin to enhance migration of chronic lymphocytic leukemia cells (2018) (26)
- Hairy Cell Leukemia, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. (2017) (26)
- Epstein-Barr virus-induced human B-cell lymphomas in SCID mice reconstituted with human peripheral blood leukocytes. (1992) (26)
- CD 40-ligand ( CD 154 ) gene therapy for chronic lymphocytic leukemia (2000) (26)
- Origin of high-grade lymphomas in Richter syndrome. (1995) (26)
- What is the CLL B-lymphocyte? (1996) (25)
- Multifunctional barcoding with ClonMapper enables high-resolution study of clonal dynamics during tumor evolution and treatment (2021) (25)
- Self‐administered, subcutaneous alemtuzumab to treat residual disease in patients with chronic lymphocytic leukemia (2011) (25)
- In vivo activation of signal transducer and activator of transcription 1 after CD154 gene therapy for chronic lymphocytic leukemia is associated with clinical and immunologic response. (2003) (24)
- Obinutuzumab (GA101) 1,000 mg versus 2,000 mg in patients with chronic lymphocytic leukemia (CLL): Results of the phase II GAGE (GAO4768g) trial. (2014) (24)
- The soluble CD 40 ligand sCD 154 in systemic lupus erythematosus (1999) (24)
- Clinical utility of assessing ZAP‐70 and CD38 in chronic lymphocytic leukemia (2006) (24)
- Molecular genetic approaches (1999) (24)
- Idiotypic cross-reactivity of immunoglobulins expressed in Waldenström's macroglobulinemia, chronic lymphocytic leukemia, and mantle zone lymphocytes of secondary B-cell follicles. (1991) (24)
- Interim Analysis of EFC6663, a Multicenter Phase 2 Study of Alvocidib (flavopiridol), Demonstrates Clinical Responses Among Patients with Fludarabine Refractory CLL (2010) (24)
- Preliminary Results of a Phase 1b Study (GP28331) Combining GDC-0199 (ABT-199) and Obinutuzumab in Patients with Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia (2014) (24)
- Association of a MicroRNA / TP 53 Feedback Circuitry With Pathogenesis and Outcome of B-Cell Chronic Lymphocytic Leukemia (2010) (24)
- Final Analysis From the International Trial of Single-Agent Ofatumumab In Patients with Fludarabine-Refractory Chronic Lymphocytic Leukemia (2010) (24)
- Trisomy 12 CLLs progress through NOTCH1 mutations (2013) (24)
- Impact of oxygen concentration on growth of mesenchymal stromal cells from the marrow of patients with chronic lymphocytic leukemia. (2013) (24)
- Plasmids encoding granulocyte-macrophage colony-stimulating factor and CD154 enhance the immune response to genetic vaccines. (2001) (24)
- Chronic lymphocytic leukemia disease progression is accelerated by APRIL-TACI interaction in the TCL1 transgenic mouse model. (2013) (23)
- A Phase I Trial of the Small Molecule Pan-Bcl-2 Family Inhibitor GX15-070 Administered Intravenously (IV) Every 3 Weeks to Patients with Previously Treated Chronic Lymphocytic Leukemia (CLL). (2005) (23)
- Developmental subtypes assessed by DNA methylation-iPLEX forecast the natural history of chronic lymphocytic leukemia. (2019) (23)
- Gene therapy of hematologic malignancies. (2000) (23)
- Leukemia-cell proliferation and disease progression in patients with early stage chronic lymphocytic leukemia (2017) (23)
- Ofatumumab monotherapy in fludarabine-refractory chronic lymphocytic leukemia: final results from a pivotal study (2015) (22)
- The generation of monoclonal anti-idiotype antibodies to human B cell-derived leukemias and lymphomas. (1985) (22)
- Outcomes with ibrutinib by line of therapy and post‐ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis (2019) (22)
- Standardization of fluorescence in situ hybridization studies on chronic lymphocytic leukemia (CLL) blood and marrow cells by the CLL Research Consortium. (2010) (22)
- Four-Year Analysis of Murano Study Confirms Sustained Benefit of Time-Limited Venetoclax-Rituximab (VenR) in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) (2019) (22)
- Safety and Efficacy Of Obinutuzumab (GA101) With Fludarabine/Cyclophosphamide (G-FC) Or Bendamustine (G-B) In The Initial Therapy Of Patients With Chronic Lymphocytic Leukemia (CLL): Results From The Phase 1b Galton Trial (GAO4779g) (2013) (21)
- NF-κB-p62-NRF2 survival signaling is associated with high ROR1 expression in chronic lymphocytic leukemia (2020) (21)
- Safety Profile and Clinical Response To MEDI-551, a Humanized Monoclonal Anti-CD19, In a Phase 1/2 Study In Adults With Relapsed Or Refractory Advanced B-Cell Malignancies (2013) (21)
- Subclonal evolution involving SF3B1 mutations in chronic lymphocytic leukemia (2013) (21)
- Immunogenetic therapy for B-cell malignancies. (2000) (21)
- Long-term Follow-up of Patients with Relapsed or Refractory Non–Hodgkin Lymphoma Treated with Venetoclax in a Phase I, First-in-Human Study (2021) (20)
- HSV amplicon-mediated delivery of LIGHT enhances the antigen-presenting capacity of chronic lymphocytic leukemia. (2002) (20)
- Williams manual of hematology (2011) (20)
- Safety and Efficacy Results from a Phase I Trial of Single-Agent Lumiliximab (Anti-CD23 Antibody) for Chronic Lymphocytic Leukemia. (2004) (20)
- Transgenic Expression of a Human Polyreactive Ig Expressed in Chronic Lymphocytic Leukemia Generates Memory-Type B Cells That Respond to Nonspecific Immune Activation1 (2004) (20)
- The Clinical Utility of Microarray-Based Gene Expression Profiling in the Diagnosis and Sub-Classification of Leukemia: Final Report on 3252 Cases from the International MILE Study Group (2008) (20)
- The long noncoding RNA, treRNA, decreases DNA damage and is associated with poor response to chemotherapy in chronic lymphocytic leukemia (2017) (20)
- Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of 2 Clinical Trials (2018) (19)
- Lenalidomide and Rituximab for the Initial Treatment of Patients with Chronic Lymphocytic Leukemia (CLL) A Multicenter Study of the CLL Research Consortium (2011) (19)
- ABT-199 (GDC-0199) combined with rituximab (R) in patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): Interim results of a phase 1b study. (2014) (19)
- Safety, Efficacy and MRD Negativity of a Combination of Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia - Results from a Phase 1b Study (GP28331) (2017) (19)
- Single‐agent ibrutinib versus chemoimmunotherapy regimens for treatment‐naïve patients with chronic lymphocytic leukemia: A cross‐trial comparison of phase 3 studies (2018) (19)
- Aurora B induces epithelial–mesenchymal transition by stabilizing Snail1 to promote basal-like breast cancer metastasis (2020) (19)
- Heat shock protein 70 regulates Tcl1 expression in leukemia and lymphomas. (2013) (19)
- miR-125a and miR-34a expression predicts Richter syndrome in chronic lymphocytic leukemia patients. (2018) (18)
- Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab (2022) (18)
- CD154 Gene Therapy for Human B‐Cell Malignancies (2005) (18)
- Transcriptomic Characterization of SF 3 B 1 Mutation Reveals Its Pleiotropic Effects in Chronic Lymphocytic Leukemia (2016) (18)
- Pharmacokinetics and Pharmacodynamics from a First-in-Human Phase 1 Dose Escalation Study with Antagonist Anti-CD40 Antibody, HCD122 (Formerly CHIR-12.12), in Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia. (2006) (18)
- Prognostic Testing Patterns and Outcomes of Chronic Lymphocytic Leukemia Patients Stratified by Fluorescence In Situ Hybridization/Cytogenetics: A Real‐world Clinical Experience in the Connect CLL Registry (2017) (18)
- CRC Clinical Trials Management System (CTMS): An Integrated Information Management Solution for Collaborative Clinical Research (2003) (18)
- New developments in flow cytometric analyses of lymphocyte markers. (1992) (18)
- Safety and efficacy of different lenalidomide starting doses in patients with relapsed or refractory chronic lymphocytic leukemia: results of an international multicenter double-blinded randomized phase II trial* (2016) (18)
- Chemoimmunotherapy with OFC in previously untreated patients with chronic lymphocytic leukemia (2011) (17)
- Selectivity in Small Molecule Splicing Modulation. (2016) (17)
- Cirmtuzumab inhibits ibrutinib-resistant, Wnt5a-induced Rac1 activation and proliferation in mantle cell lymphoma (2018) (17)
- Up to seven years of follow-up in the RESONATE-2 study of first-line ibrutinib treatment for patients with chronic lymphocytic leukemia. (2021) (17)
- Outcomes with ibrutinib by line of therapy in patients with CLL: Analyses from phase III data. (2016) (17)
- A general process for the development of peptide-based immunoassays for monoclonal antibodies (2010) (17)
- Aberrant and unstable expression of immunoglobulin genes in persons infected with human immunodeficiency virus. (1998) (17)
- INTEGRATED ANALYSIS: OUTCOMES OF IBRUTINIB‐TREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LEUKEMIA (CLL/SLL) WITH HIGH‐RISK PROGNOSTIC FACTORS (2017) (17)
- Clinical Activity Of Idelalisib (GS-1101), a Selective Inhibitor Of PI3Kδ, In Phase 1 and 2 Trials In Chronic Lymphocytic Leukemia (CLL): Effect Of Del(17p)/TP53 Mutation, Del(11q), IGHV Mutation, and NOTCH1 Mutation (2013) (17)
- Efficacy results of a phase 2 trial of first-line idelalisib plus ofatumumab in chronic lymphocytic leukemia. (2019) (17)
- Wnt5a induces ROR1 to recruit cortactin to promote breast-cancer migration and metastasis (2019) (17)
- Pattern of Use of Anticoagulation and/or Antiplatelet Agents in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Single-Agent Ibrutinib Therapy (2014) (17)
- Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trial (2016) (16)
- Dielectrophoretic recovery of DNA from plasma for the identification of chronic lymphocytic leukemia point mutations. (2016) (16)
- A randomized, multicenter, open-label, phase III study of the Bruton tyrosine kinase (BTK) inhibitor ibrutinib (PCI-32765) versus ofatumumab in patients (pts) with relapsed or refractory (RR) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): RESONATE. (2013) (16)
- Single nucleotide polymorphisms and inherited risk of chronic lymphocytic leukemia among African Americans. (2012) (16)
- Wnt5a enhances proliferation of chronic lymphocytic leukemia and ERK1/2 phosphorylation via a ROR1/DOCK2-dependent mechanism (2020) (16)
- Fixed-duration (FD) first-line treatment (tx) with ibrutinib (I) plus venetoclax (V) for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Primary analysis of the FD cohort of the phase 2 captivate study. (2021) (16)
- IGHV1-69-Encoded Antibodies Expressed in Chronic Lymphocytic Leukemia React with Malondialdehyde–Acetaldehyde Adduct, an Immunodominant Oxidation-Specific Epitope (2013) (16)
- Proteomic Analysis of Chronic Lymphocytic Leukemia Cells Identifies Vimentin as a Novel Prognostic Factor for Aggressive Disease. (2005) (15)
- Expression of Ig-beta (CD79b) by chronic lymphocytic leukemia B cells that lack immunoglobulin heavy-chain allelic exclusion. (2000) (15)
- Efficacy of idelalisib in CLL subpopulations harboring del(17p) and other adverse prognostic factors: Results from a phase 3, randomized, double-blind, placebo-controlled trial (2014) (15)
- Efficacy of venetoclax plus rituximab for relapsed CLL: Five-year follow-up of continuous or limited-duration therapy. (2021) (15)
- Systemic mastocytosis in association with chronic lymphocytic leukemia and plasma cell myeloma. (2010) (15)
- Local and systemic effects after adenoviral transfer of the murine granulocyte–macrophage colony‐stimulating factor gene into mice (2000) (15)
- Characterization of the 13 q 14 Tumor Suppressor Locus in CLL : Identification of ALT 1 , an Alternative Splice Variant of the LEU 2 Gene 1 (2001) (14)
- Long-term efficacy and safety with ibrutinib (ibr) in previously treated chronic lymphocytic leukemia (CLL): Up to four years follow-up of the RESONATE study. (2017) (14)
- Advances in classification and therapy of indolent B-cell malignancies. (2002) (14)
- Recurrent XPO1 mutations alter pathogenesis of chronic lymphocytic leukemia (2021) (14)
- Characterizing the kinetics of lymphocytosis in patients with chronic lymphocytic leukemia treated with single-agent ibrutinib (2018) (14)
- Autoantibody production in Sjögren's syndrome: a hypothesis regarding defects in somatic diversification of germ line encoded genes. (1988) (14)
- Chemical biology strategy reveals pathway-selective inhibitor of NF-kappaB activation induced by protein kinase C. (2010) (14)
- Cyclic nucleotide phosphodiesterase 7B mRNA: An unfavorable characteristic in chronic lymphocytic leukemia (2011) (14)
- Lumiliximab in combination with FCR for the treatment of relapsed chronic lymphocytic leukemia (CLL): results from a phase I/II multicenter study (2008) (13)
- Zilovertamab Vedotin Targeting of ROR1 as Therapy for Lymphoid Cancers (2021) (13)
- Second interim analysis of a phase 3 study evaluating idelalisib and rituximab for relapsed CLL. (2014) (13)
- A hotspot mutation in transcription factor IKZF3 drives B cell neoplasia via transcriptional dysregulation. (2021) (13)
- Signal transduction pathways and mechanisms of apoptosis in CLL B-lymphocytes: their role in CLL pathogenesis. (1997) (13)
- Safety, efficacy and immune effects of venetoclax 400 mg daily in patients with relapsed chronic lymphocytic leukemia (CLL). (2016) (13)
- A phase 2 study of idelalisib plus rituximab in treatment-na¨ ı ve older patients with chronic lymphocytic leukemia (2015) (13)
- Comparison of familial and sporadic chronic lymphocytic leukaemia using high resolution array comparative genomic hybridization (2010) (13)
- Regulation of antibody heterogeneity by suppressor T cells: diminishing suppressor T cell activity increases the number of dinitrophenyl clones in mice immunized with dinitrophenyl-poly(Glu,Lys,Phe) or dinitrophenyl-poly(Glu,Lys,Ala). (1978) (13)
- Genetic analysis of human B cell hybridomas expressing a cross-reactive idiotype. (1987) (13)
- Gene therapy and active immune therapy of hematologic malignancies. (2007) (13)
- Laser microdissection for the assessment of the clonal relationship between chronic lymphocytic leukemia/small lymphocytic lymphoma and proliferating B cells within lymph node pseudofollicles (2011) (12)
- Quantitative Proteomics to Characterize Specific Histone H2A Proteolysis in Chronic Lymphocytic Leukemia and the Myeloid THP-1 Cell Line (2014) (12)
- Advances in classification and therapy of indolent B-cell malignancies. (2002) (12)
- A multicenter phase 1 study of plerixafor and rituximab in patients with chronic lymphocytic leukemia (2019) (12)
- Randomized, multicenter, open-label, phase 3 study of the BTK inhibitor ibrutinib in combination with obinutuzumab vs. chlorambucil in combination with obinutuzumab in patients with treatment-naïve CLL/SLL (PCYC-1130): iLLUMINATE. (2015) (12)
- Genetics of chronic lymphocytic leukaemia. (2000) (12)
- PHASE 2 STUDY OF ACALABRUTINIB IN IBRUTINIB‐INTOLERANT PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (2019) (12)
- Impact of long-term ibrutinib treatment on circulating immune cells in previously untreated chronic lymphocytic leukemia. (2021) (12)
- Molecular map of chronic lymphocytic leukemia and its impact on outcome (2022) (12)
- Ofatumumab and high-dose methylprednisolone for the treatment of patients with relapsed or refractory chronic lymphocytic leukemia (2014) (12)
- SET alpha and SET beta mRNA isoforms in chronic lymphocytic leukaemia (2018) (12)
- The BCL-2-Specific BH3-Mimetic ABT-199 (GDC-0199) Is Active and Well-Tolerated in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Interim Results of a Phase I First-in-Human Study (2012) (12)
- Durability of Responses on Continuous Therapy and Following Drug Cessation with Venetoclax and Rituximab: Long-Term Follow-up Analysis of a Phase 1b Study in Patients with Relapsed CLL (2019) (12)
- Institute-Working Group (NCI-WG) 1996 guidelines Lymphocytic Leukemia (IWCLL) updating the National Cancer leukemia: a report from the International Workshop on Chronic Guidelines for the diagnosis and treatment of chronic lymphocytic (2008) (12)
- Exploring the Pathways to Chronic Lymphocytic Leukemia. (2021) (12)
- Longitudinal single-cell dynamics of chromatin accessibility and mitochondrial mutations in chronic lymphocytic leukemia mirror disease history. (2021) (12)
- Activation of hedgehog signaling associates with early disease progression in chronic lymphocytic leukemia. (2019) (12)
- Safety and Efficacy of Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) and Coexisting Medical Conditions: Final Results of the Run-in Phase of the Randomized CLL14 Trial (BO25323) (2016) (12)
- A phase I study of escalated dose subcutaneous alemtuzumab given weekly with rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma (2013) (12)
- 11q Deletion (del11q) Is Not a Prognostic Factor for Adverse Outcomes for Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Treated with Ibrutinib: Pooled Data from 3 Randomized Phase 3 Studies (2016) (11)
- Cirmtuzumab Vedotin (UC-961ADC3), An Anti-ROR1-Monomethyl Auristatin E Antibody-Drug Conjugate, Is a Potential Treatment For ROR1-Positive Leukemia and Solid Tumors (2013) (11)
- An Ongoing Phase 1/2a Study of ABT-263; Pharmacokinetics (PK), Safety and Anti-Tumor Activity in Patients (pts) with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL). (2008) (11)
- [Analysis of the restricted dinitrophenyl (DNP) antibody response to the DNP conjugate of poly-(L-Glu56, L-LYS35, L-PHE9)]. (1978) (11)
- Ibrutinib reduces obinutuzumab infusion-related reactions in patients with chronic lymphocytic leukemia and is associated with changes in plasma cytokine levels (2020) (11)
- Immune and cell therapy of hematologic malignancies (2002) (11)
- Rituximab in chronic lymphocytic leukemia (2011) (11)
- Human B cell biology. (1997) (11)
- Correlation Between Serum Ofatumumab Concentrations, Baseline Patient Characteristics and Clinical Outcomes in Patients with Fludarabine-Refractory Chronic Lymphocytic Leukemia (CLL) Treated with Single-Agent Ofatumumab. (2009) (11)
- MURANO Trial Establishes Feasibility of Time-Limited Venetoclax-Rituximab (VenR) Combination Therapy in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) (2018) (11)
- Translocation t(2;11) in CLL cells results in CXCR4/MAML2 fusion oncogene. (2014) (10)
- Ibrutinib Versus Ofatumumab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Results From the Randomized Phase III RESONATE™ (PCYC-1112) Trial (2015) (10)
- Randomized comparison of ibrutinib versus ofatumumab in relapsed or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma: Results from the phase III RESONATE trial. (2014) (10)
- Phase 1/2 study of cirmtuzumab and ibrutinib in mantle cell lymphoma (MCL) or chronic lymphocytic leukemia (CLL). (2021) (10)
- A Phase I/II Trial of Xcellerated T Cells™ in Patients with Chronic Lymphocytic Leukemia. (2004) (10)
- Plasma B-Cell Maturation Antigen Levels are Elevated and Correlate with Disease Activity in Patients with Chronic Lymphocytic Leukemia (2015) (10)
- NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 3.2022. (2022) (10)
- Rituximab and High-Dose Methylprednisolone for the Initial Treatment of Chronic Lymphocytic Leukemia Is Associated with Promising Clinical Activity and Minimal Hematologic Toxicity (2008) (10)
- Idiotypes in biology and medicine. (1989) (10)
- Treatment of solid tumors with immunotoxins (2005) (10)
- Obinutuzumab plus fl udarabine / cyclophosphamide or bendamustine in the initial therapy of CLL patients : the phase 1 b GALTON trial (2015) (10)
- Ofatumumab and High-Dose Methylprednisolone Is An Effective Salvage Treatment for Heavily Pretreated, Unfit or Refractory Patients with Chronic Lymphocytic Leukemia: Single Institution Experience (2010) (10)
- Future strategies toward the cure of indolent B-cell malignancies. Molecular genetic approaches. (1999) (10)
- Regulation of rheumatoid factor synthesis. (1989) (9)
- The Cell Surface Receptor CD44: NMR‐Based Characterization of Putative Ligands (2016) (9)
- Lumiliximab with fludarabine, cyclophosphamide, and rituximab (FCR) for patients with relapsed chronic lymphocytic leukemia (CLL). (2006) (9)
- ROR1 - An Orphan Becomes Apparent. (2022) (9)
- Distinct evolutionary paths in chronic lymphocytic leukemia during resistance to the graft-versus-leukemia effect (2020) (9)
- Randomized, multicenter, open-label, phase III study of the BTK inhibitor ibrutinib versus chlorambucil in patients 65 years or older with treatment-naive CLL/SLL (RESONATE-2, PCYC-1115-CA). (2013) (9)
- IgVH Mutational Status Does Not Affect Complete Remission Rate but Is Associated with Reduced Remission Duration in CLL Patients Treated with Fludarabine, Cyclophosphamide and Rituximab (FCR)-Based Therapy. (2007) (9)
- Aberrant and Unstable Expression of Immunoglobulin Genes in Persons Infected With Human Immunodeficiency Virus (1998) (9)
- Adenovirus transduction to effect CD40 signalling improves the immune stimulatory activity of myeloma cells (2002) (9)
- Molecular basis for the cross-reactive idiotypes on human anti-IgG autoantibodies (rheumatoid factors). (1987) (9)
- Chronic lymphocytic leukemia associated with immunotactoid glomerulopathy: a case report of successful treatment with high-dose methylprednisolone in combination with rituximab followed by alemtuzumab (2012) (9)
- AT 101, an Inhibitor of Bcl-2 Family Members Is Cytotoxic to a Heterogeneous Group of CLL Samples and Synergistic with Rituximab. (2005) (9)
- Targeted Therapy in Chronic Lymphocytic Leukemia (2019) (9)
- Restricted Expression of the Orphan Tyrosine Kinase Receptor ROR1 in Chronic Lymphocytic Leukemia. (2004) (9)
- AT-101, a Pan-Inhibitor of Bcl-2 Family Anti-Apoptotic Proteins Antagonizes the Protective Effect Conferred by Nurselike Cells on Primary Chronic Lymphocytic Leukemia (CLL) Cells. (2006) (8)
- Integrated and Long-Term Safety Analysis of Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (2016) (8)
- Lenalidomide Abrogates the Protective Influence of Nurse-Like Cells on Primary Chronic Lymphocytic Leukemia Cells In Vitro. (2007) (8)
- Dasatinib Induces Apoptosis in Chronic Lymphocytic Leukemia and Enhances the Activity of Rituximab and Fludarabine. (2007) (8)
- Phase 2 study of acalabrutinib in ibrutinib (IBR)-intolerant patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). (2019) (8)
- Prolonged Improvement in Patient-Reported Outcomes (PROs) and Well-being in Older Patients With Treatment-Naïve (TN) Chronic Lymphocytic Leukemia Treated With Ibrutinib (Ibr): 3-Year Follow-up of the RESONATE-2 Study (2017) (8)
- Preclinical Development Of ROR1 Peptide Based Vaccine With Activity Against Chronic Lymphocytic Leukemia In ROR1 Transgenic Mice (2013) (8)
- Chronic lymphocytic leukemia. (1999) (8)
- cyCombine allows for robust integration of single-cell cytometry datasets within and across technologies (2022) (8)
- Tumour debulking and reduction in predicted risk of tumour lysis syndrome with single‐agent ibrutinib in patients with chronic lymphocytic leukaemia (2019) (8)
- HNRNPL Restrains miR-155 Targeting of BUB1 to Stabilize Aberrant Karyotypes of Transformed Cells in Chronic Lymphocytic Leukemia (2019) (8)
- Preliminary Results of a Phase II Open-Label, Randomized Study of the BH3 Mimetic Protein Navitoclax (ABT-263) with or without Rituximab for Treatment of Previously Untreated B-Cell Chronic Lymphocytic Leukemia (2012) (8)
- Analysis of CLLU1 expression levels before and after therapy in patients with chronic lymphocytic leukemia (2011) (8)
- Single-Agent Ibrutinib Vs Chemoimmunotherapy Regimens for Treatment-Naïve Patients with Chronic Lymphocytic Leukemia (CLL): A Cross-Trial Comparison (2017) (8)
- Switching the Isotype of Monoclonal Antibodies (1985) (8)
- LONG‐TERM EFFICACY AND SAFETY IN THE RESONATE STUDY: IBRUTINIB IN PATIENTS WITH PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH UP TO FOUR YEARS FOLLOW‐UP (2017) (8)
- First-Line Treatment with Ibrutinib (Ibr) Plus Venetoclax (Ven) for Chronic Lymphocytic Leukemia (CLL): 2-Year Post-Randomization Disease-Free Survival (DFS) Results from the Minimal Residual Disease (MRD) Cohort of the Phase 2 Captivate Study (2021) (7)
- A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib and Rituximab for Previously Treated Patients with Chronic Lymphocytic Leukemia (CLL) (2013) (7)
- Retraction: The triterpenoid CDDO-Imidazolide induces apoptosis and enhances fludarabine-induced apoptosis of CLL B-cells. (2004) (7)
- Oxaliplatin, Fludarabine, Cytarabine, and Rituximab Combination Therapy Induces High Response Rates in Agressive Chronic Lymphocytic Leukemia (CLL) and Richter's Syndrome (RS). (2009) (7)
- Sequential modulation of growth factors: a novel strategy for adoptive immunotherapy of acute myeloid leukemia. (2002) (7)
- Expression of an Ig VH Gene, 51p1, Is Proportional to Its Germline Gene Copy Number (1997) (7)
- BMS-936564 (Anti-CXCR4 Antibody) Induces Specific Leukemia Cell Mobilization and Objective Clinical Responses In CLL Patients Treated Under a Phase I Clinical Trial (2013) (7)
- Immunoglobulin V gene utilization in chronic lymphocytic leukemia and non-Hodgkin's B cell lymphomas. (1988) (7)
- Durability of Responses on Continuous Therapy and Following Drug Cessation in Deep Responders with Venetoclax and Rituximab (2018) (7)
- Development of Cirmtuzumab Antibody-Drug Conjugates (ADCs) Targeting Receptor Tyrosine Kinase-like Orphan Receptor 1 (ROR1) (2018) (7)
- Rituximab in combination with high-dose methylprednisolone for the treatment of chronic lymphocytic leukemia (2009) (7)
- Phase 1/2 trial of cirmtuzumab and ibrutinib: Planned analysis of phase 1 CLL cohorts. (2019) (7)
- Durable remissions with obinutuzumab-based chemoimmunotherapy: long-term follow-up of the phase 1b GALTON trial in CLL. (2019) (7)
- **102 Chemoimmunotherapy with Ofatumumab, Fludarabine and Cyclophosphamide (O-FC) in Previously Untreated Patients with Chronic Lymphocytic Leukemia (2011) (7)
- MEDI-551, an anti-CD19 antibody active in chronic lymphocytic leukemia (CLL) patients previously treated with rituximab. (2013) (7)
- Chimeric form of tumor necrosis factor-α has enhanced surface expression and antitumor activity (2009) (7)
- A Multi-Center and Multi-National Program To Assess the Clinical Accuracy of the Molecular Subclassification of Leukemia by Gene Expression Profiling. (2005) (7)
- Anti-CD20 Antibody Rituximab and Anti-CD23 Antibody IDEC-152 Induce Apoptosis of Malignant B-Cells in Combination with Chemical Antagonists of XIAP. (2004) (6)
- High expression level of ROR1 and ROR1-signaling associates with venetoclax resistance in chronic lymphocytic leukemia (2022) (6)
- Preneoplastic Alterations Define CLL DNA Methylome and Persist through Disease Progression and Therapy. (2020) (6)
- Analyses of Recombinant Stereotypic IGHV3-21–Encoded Antibodies Expressed in Chronic Lymphocytic Leukemia (2011) (6)
- Polygenic risk score and risk of monoclonal B-cell lymphocytosis in caucasians and risk of chronic lymphocytic leukemia (CLL) in African Americans (2021) (6)
- Activation of Notch and Myc Signaling via B-cell–Restricted Depletion of Dnmt3a Generates a Consistent Murine Model of Chronic Lymphocytic Leukemia (2021) (6)
- Clinical roundtable monograph. New alternatives in CLL therapy: managing adverse events. (2010) (6)
- ZUMA-2: A phase 2 multi-center study evaluating the efficacy of KTE-C19 (Anti-CD19 CAR T cells) in patients with relapsed/refractory Mantle cell lymphoma (R/R MCL) (2016) (6)
- Investigating the Addition of Ianalumab (VAY736) to Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL) on Ibrutinib Therapy: Results from a Phase Ib Study (2021) (6)
- TP53 Mutation or Deletion and Efficacy with Single-Agent Lenalidomide in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) (CC-5013-CLL-009 Study) (2013) (6)
- Association Between the Proficiency of B-Cell Receptor Signaling and the Relative Expression Levels of ZAP-70, SHIP-1, and Mir-155 in Chronic Lymphocytic Leukemia (2008) (6)
- Autoantibodies against p53 are associated with chromosome 17p deletions in chronic lymphocytic leukemia. (2011) (6)
- 5.23 Phase 2 Study of Navitoclax (ABT-263) Safety and Efficacy in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Interim Results (2011) (5)
- CRC Tissue Core Management System (TCMS): Integration of Basic Science and Clinical Data for Translational Research (2003) (5)
- Updated Interim Results of the Safety and Efficacy of Different Lenalidomide Starting Dose Regimens in Patients with Relapsed or Refractory (rel/ref) Chronic Lymphocytic Leukemia (CLL) (CC-5013-CLL-009 Study) (2012) (5)
- Increased aldehyde dehydrogenase activity in high-risk chronic lymphocytic leukemia (2013) (5)
- Genomic complexity in chronic lymphocytic leukemia. (2008) (5)
- Survival adjusting for crossover: phase 3 study of ibrutinib vs. chlorambucil in older patients with untreated chronic lymphocytic leukemia/small lymphocytic lymphoma (2017) (5)
- Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studies (2022) (5)
- leukemia by regulating expression of GAB1 and FOXP1 miR-150 influences B-cell receptor signaling in chronic lymphocytic (2014) (5)
- Combination of Oxaliplatin, Fludarabine, Cytarabine, and Rituximab in Richter’s Syndrome and Fludarabine-Refractory Chronic Lymphocytic Leukemia. (2006) (5)
- Chronic Lymphocytic Leukemia Patients with IGHV Genes Carrying Only Silent Mutations Have A Longer Time From Diagnosis to Initial Therapy Than Patients Expressing B-Cell Receptors with No Somatic Mutations (2011) (5)
- Alemtuzumab in chronic lymphocytic leukemia. (2007) (5)
- Results of a Phase I-II Clinical Trial of Oxaliplatin, Fludarabine, Cytarabine, and Rituximab (OFAR) Combination Therapy In Patients with Aggressive, Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Richter Syndrome (RS) (2010) (5)
- Cirmtuzumab, an Anti-ROR1 Antibody, in Combination with Ibrutinib: Clinical Activity in Mantle Cell Lymphoma (MCL) or Chronic Lymphocytic Leukemia (CLL) from a Phase 1/2 Study (2020) (5)
- A phase II study of the combination of rituximab and granulocyte macrophage colony stimulating factor as treatment of patients with chronic lymphocytic leukemia (2015) (5)
- GX15–070MS, a synthetic small molecule induces apoptosis in vitro and in vivo in chronic lymphocytic leukemia (2005) (5)
- Interim Results for the Safety and Efficacy of Different Lenalidomide Starting Dose Regimens in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia (CC-5013-CLL-009 Study) (2011) (5)
- Results from the international, randomized phase 3 study of ibrutinib versus chlorambucil in patients 65 Years and older with treatment-naive (TN) CLL/SLL (RESONATE-2 (TM)) (2015) (5)
- Self-Administered, Subcutaneous (SQ) Alemtuzumab To Eliminate Residual Disease in Patients (pts) with CLL. (2006) (5)
- A cross-trial comparison of single-agent ibrutinib versus chlorambucil-obinutuzumab in previously untreated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (2020) (5)
- BMS-936564 (MDX1338): A Fully Human Anti-CXCR4 Antibody Induces Apoptosis in an in Vitro Model of Stromal – Leukemia Cell Interaction for Chronic Lymphocytic Leukemia. (2012) (5)
- Health-related quality of life (HRQL) impact of idelalisib (IDELA) in patients (pts) with relapsed chronic lymphocytic leukemia (CLL): Phase 3 results. (2014) (5)
- Ofatumumab Combined With Fludarabine and Cyclophosphamide (O-FC) Shows High Activity in Patients With Previously Untreated Chronic Lymphocytic Leukemia: Results From a Randomized, Multicenter, International, Two-Dose, Parallel-Group Phase II Trial (2010) (5)
- Elements of the Human Immune System: Studies of Mature Lymphoid Cells Following Xenotransplantation to Scid Mice (1989) (5)
- Intratumoral delivery of CD154 homolog (Ad-ISF35) induces tumor regression: analysis of vector biodistribution, persistence and gene expression (2012) (5)
- An open-label, single-arm, phase 1 study to assess biomarker effects, efficacy and safety of ofatumumab in patients with refractory chronic lymphocytic leukemia (2015) (4)
- Adoptive cellular therapy for chronic lymphocytic leukemia and B cell malignancies. CARs and more. (2016) (4)
- Immunoglobulin Idiotypes in Human B Cell Neoplasia (1990) (4)
- Tcl 1 interacts with Atm and enhances NF-kB activation in hematological malignancies (2011) (4)
- Mir-155 Contributed to Chronic Lymphocytic Leukemia Survival by Modulation of BCR-Signalling (2011) (4)
- Single-Agent Ibrutinib Versus Chlorambucil-Obinutuzumab As First-Line Treatment in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL): Results of a Cross-Trial Comparison (2018) (4)
- Ad-ISF35-Transduced Autologous Cells In Combination with Fludarabine, Cyclophosphamide, Rituximab (FCR) Induces Complete and Partial Responses In a Phase 1b Study for Patients with Fludarabine-Refractory and/or Del(17p)/p53-Defective Chronic Lymphocytic Leukemia (CLL) (2011) (4)
- Cirmtuzumab (UC-961), a First-in-Class Anti-ROR1 Monoclonal Antibody: Planned Interim Analysis of Initial Phase 1 Cohorts (2015) (4)
- Dynamic changes in CCL3 and CCL4 plasma concentrations in patients with chronic lymphocytic leukaemia managed with observation (2018) (4)
- First Prospective Data on Impact of Minimal Residual Disease on Long-Term Clinical Outcomes after Venetoclax Plus Rituximab Versus Bendamustine Plus Rituximab: Phase III MURANO Study (2018) (4)
- Recent Advances in CAR T-Cell Therapy for Patients with Chronic Lymphocytic Leukemia (2022) (4)
- Outcomes of First-Line Ibrutinib in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and High-Risk Genomic Features with up to 6.5 Years Follow-up: Integrated Analysis of Two Phase 3 Studies (RESONATE-2 and iLLUMINATE) (2020) (4)
- Ibrutinib for Chronic Lymphocytic Leukemia. (2016) (4)
- Extending genetic vaccines with chemokines (1999) (4)
- Intratumoral injection of Ad-ISF35 (Chimeric CD154) breaks tolerance and induces lymphoma tumor regression. (2015) (4)
- Clinical improvement with a novel CD20 mAb, ofatumumab, in fludarabine-refractory chronic lymphocytic leukemia (CLL) also refractory to alemtuzumab or with bulky lymphadenopathy. (2016) (4)
- Patterns of Care for Patients with Chronic Lymphocytic Leukemia (CLL): The Connect ® CLL Disease Registry (2011) (4)
- Value of computed tomography in the monitoring of patients with chronic lymphocytic leukemia. (2007) (4)
- Comparative Evaluation of Prognostic Factors That Assess the Natural History of Chronic Lymphocytic Leukemia (2016) (4)
- MEDI-551, a Humanized Monoclonal Anti-CD19, in Adults with Relapsed or Refractory Advanced B-Cell Malignancies: Results From a Phase 1/2 Study (2012) (4)
- Chemoimmunotherapy with ofatumumab, fludarabine, and cyclophosphamide (O-FC) in previously untreated patients with chronic lymphocytic leukemia (CLL). (2010) (4)
- An evaluation of the chronic lymphocytic leukemia (CLL) international prognostic index as a prognostic tool in patients with relapsed/refractory CLL in idelalisib phase 3 randomized studies. (2016) (3)
- Gene Therapy of Chronic Lymphocytic Leukemia (2004) (3)
- Immunoglobulin idiotypes in human B cell neoplasia. Implications for pathogenesis and therapy. (1990) (3)
- FOXP1 genes chronic lymphocytic leukemia by regulating expression of GAB1 and MicroRNA-150 contributes to the proficiency of B-cell receptor signaling in (2014) (3)
- Variation in health-related quality of life (HRQOL) by ECOG performance status (PS) and fatigue among patients with chronic lymphocytic leukemia (CLL). (2012) (3)
- Clinical activity of cirmtuzumab, an anti-ROR1 antibody, in combination with ibrutinib: Interim results of a phase Ib/II study in mantle cell lymphoma (MCL) or chronic lymphocytic leukemia (CLL). (2020) (3)
- Immunotherapeutic Targeting of ROR1-Dependent, Non-Canonical Wnt5a-Signaling By Cirmtuzumab: A First-in-Human Phase I Trial for Patients with Intractable Chronic Lymphocytic Leukemia (2016) (3)
- Abstract CT158: Unmutated IGHV is not an adverse predictor of outcome to therapy with ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (2017) (3)
- and Treatment of Chronic Lymphocytic Leukemia (2003) (3)
- Multicenter, phase III, open-label, randomized study in relapsed/refractory CLL to evaluate the benefit of GDC-0199 (ABT-199) plus rituximab compared with bendamustine plus rituximab. (2014) (3)
- Role of Ts-RNAs in CLL (2016) (3)
- Expression of MicroRNA (miR) miR-15a/miR-16-1 Downregulates Expression of BCL-2 Protein in Chronic Lymphocytic Leukemia. (2006) (3)
- Activity of ofatumumab, a novel CD20 mAb, and prior rituximab exposure in patients with fludarabine- and alemtuzumab-refractory or bulky fludarabine-refractory chronic lymphocytic leukemia (CLL). (2016) (3)
- Lenalidomide and rituximab for the initial treatment of chronic lymphocytic leukemia: Report of an ongoing study. (2010) (3)
- Genetic Determinants and Evolutionary History of Richter's Syndrome (2020) (3)
- Comprehensive Bulk and Single Cell Transcriptomic Characterization of SF3B1 Mutation Reveals Its Pleiotropic Effects in Chronic Lymphocytic Leukemia (2015) (3)
- Relative Value of CD38 and ZAP-70 Versus Immunoglobulin Mutation Status in Predicting Early Disease Progression in Chronic Lymphocytic Leukemia. (2006) (3)
- Safety and disease response to MEDI-551, an anti-CD19 antibody, in chronic lymphocytic leukemia patients previously treated with rituximab (2013) (3)
- Immunoglobulin Gene Rearrangement and Expression in B-CLL. (1991) (3)
- Genetic mapping of the BGL idiotypic marker within theIgh-V region (1979) (3)
- Abstract P3-10-18: Phase 1b trial of cirmtuzumab and paclitaxel for locally advanced, unresectable and metastatic breast cancer (2020) (3)
- Kinetic Measurement of Leukemia-Cell Proliferation Rate By Deuterium Labeling Predicts Time to Initial Treatment of Patients with Chronic Lymphocytic Leukemia (2014) (3)
- Membrane-Stable, Humanized CD154 Gene Therapy for Patients with CLL. (2006) (3)
- Lenalidomide Administered for the Initial Treatment of Chronic Lymphocytic Leukemia (CLL) Patients- In Vivo Modulation of the Leukemia Cell Surface Phenotype and Association with Tumor Flare Reaction (TFR). (2009) (3)
- Oral fludarabine in untreated patients with B-cell chronic lymphocytic leukemia (2010) (3)
- A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) Phase II Study of Oral Fludarabine in Untreated B-Cell Chronic Lymphocytic Leukemia. (2005) (3)
- Evolutionary history of transformation from chronic lymphocytic leukemia to Richter syndrome (2022) (3)
- Targeting of Chronic Lymphocytic Leukemia B Cells with a Novel Monoclonal Antibody to ROR1 (2011) (3)
- Ofatumumab, a Novel CD20 Monoclonal Antibody, Is Active in Patients With Fludarabine- and Alemtuzumab-Refractory or Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia Irrespective of Prior Rituximab (2009) (3)
- Preneoplastic Alterations Define CLL DNA Methylome and Persist through Disease Progression and Therapy. (2021) (3)
- Improvement in quality of life and well-being in older patients with treatment-naive (TN) CLL : results from the randomized phase 3 study of ibrutinib (IBR) versus chlorambucil (CLB) (resonate-2™) (2016) (3)
- Genetic dynamics in untreated CLL patients with either stable or progressive disease: a longitudinal study (2019) (3)
- Phenotypic Changes Associated with Acute Reductions In Leukemia Cell Counts In Patients with Chronic Lymphocytic Leukemia (CLL) Receiving Lenalidomide as Initial Therapy (2010) (3)
- A6 Peptide Is Selectively Cytotoxic For Chronic Lymphocytic Leukemia Cells (2013) (3)
- Phase I study of intranodal direct injection of adenovirus encoding recombinant CD40-ligand (Ad-ISF35) in patients with chronic lymphocytic leukemia. (2009) (3)
- IMPACT OF MAJOR GENOMIC ALTERATIONS ON OUTCOME OF RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS RECEIVING VENETOCLAX PLUS RITUXIMAB IN THE PHASE 3 MURANO STUDY (2019) (3)
- Pharmacokinetics of Single-Agent Lumiliximab (Anti-CD23 Antibody) in Patients with Chronic Lymphocytic Leukemia. (2004) (3)
- CD38 Compared with ZAP-70 or Immmunoglobulin Mutation Status as Predictor of Disease Progression in Chronic Lymphocytic Leukemia. (2004) (3)
- The Aberrantly Expressed Long Noncoding RNA, TRERNA1, Predicts for Aggressive Disease in Chronic Lymphocytic Leukemia (2015) (3)
- NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma, Version 4.2020 (2020) (3)
- Cross-Study Multivariable Analysis of the Impact of Adding Rituximab to Venetoclax on the Depth and Durability of Response in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (2016) (3)
- Constitutive Baff Signalling Plays a Key Role in CLL Development by Promoting Tumor Cell Survival (2008) (3)
- B-cell Receptor Signaling Induced Metabolic Alterations in Chronic Lymphocytic Leukemia Can Be Partially Bypassed by TP53 Abnormalities (2022) (3)
- The CLL-1100 Project: Towards Complete Genomic Characterization and Improved Prognostics for CLL (2020) (3)
- A Phase I Study of Escalated Dose Subcutaneous Alemtuzumab Given Weekly with Rituximab In Relapsed CLL/SLL. (2010) (3)
- Inhibition of Wnt Signaling By Dimethyl Fumarate Results in in Vitro and in Vivo Clearance of Chronic Lymphocytic Leukemia Cells and Has Additive Activity with Ibrutinib (2014) (3)
- Wnt5a Induces ROR1 to Complex with HS1, Which Undergoes Tyrosine Phosphorylation and Contributes to Planar-Cell-Polarity Migration in Chronic Lymphocytic Leukemia (2016) (3)
- Percentage of Smudge Cells on Blood Smear Predicts Prognosis in Chronic Lymphocytic Leukemia: A Multicenter Study. (2007) (3)
- Antigen receptor signaling in CLL—is the line dead? (2003) (3)
- Cirmtuzumab Inhibits Non-Canonical Wnt Signaling without Enhancing Canonical Wnt/β-Catenin Signaling in Chronic Lymphocytic Leukemia (2018) (3)
- Demographics By Age Group (AG) and Line of Therapy (LOT) in Chronic Lymphocytic Leukemia (CLL) Patients (Pts) Treated in US Practices from the Connect® CLL Registry (2014) (3)
- A Phase Ib/II Study of Ibrutinib in Combination with Obinutuzumab-Gazyva As First-Line Treatment for Patients with Chronic Lymphocytic Leukemia > 65 Years Old or with Coexisting Conditions (2016) (3)
- Chronic lymphocytic leukemia ZAP-70 and the b-cell receptor (2007) (3)
- An International Multi-Center Study To Define the Application of Microarrays in the Diagnosis and Subclassification of Leukemia (MILE Study): Interim Analysis Based on 1,889 Patients Achieves 95.4% Prediction Accuracy. (2006) (3)
- A Phase Ib/II Study of Combined Obinutuzumab (Gazyva) and High-Dose Methylprednisolone (HDMP) As Treatment for Patients with Chronic Lymphocytic Leukemia (CLL) (2015) (3)
- Combined ROR1 and CD160 Detection For Improved Minimal Residual Disease In Patients With Chronic Lymphocytic Leukemia (CLL) (2013) (2)
- Characterization of CD4 cytotoxic T cells specific for autologous chronic lymphocytic leukemia B cells (2000) (2)
- Analysis of Quality of Life and Well-being from the Randomized Phase 3 Study of Ibrutinib Versus Chlorambucil in Older Patients with Treatment-naïve CLL (RESONATE-2TM) (2016) (2)
- High-Level ROR1 and BCL2, Cancer-Stemness, and BCL2 Mutations Associate with Venetoclax Resistance in Chronic Lymphocytic Leukemia (2019) (2)
- Comparison of T and B cell reactivity to antigens under Ir gene control. (1980) (2)
- Analysis of Prognostic Factors Predictive of Complete Response (CR) to Ibrutinib in Patients with CLL/SLL (2015) (2)
- Rituximab® and High Dose Methylprednisolone (HDMP) for the Treatment of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia. (2004) (2)
- Variation in Health-Related Quality of Life by Line of Therapy of Patients with Chronic Lymphocytic Leukemia (2012) (2)
- A Highly Selective Anti-ROR1 Monoclonal Antibody Inhibits Human Acute Myeloid Leukemia CD34+ Cell Survival and Self-Renewal. (2012) (2)
- Long-Term Sustained Responses Following Ibrutinib Discontinuation after Frontline Therapy with Obinutuzumab Plus Ibrutinib in Patients with Chronic Lymphocytic Leukemia (2020) (2)
- Abstract 950: Selective cytotoxicity of A6 peptide against ZAP-70 expressing CLL B-cells (2014) (2)
- Fd-895 and Pladienolide B Inhibit mRNA Splicing and Induce Apoptosis in Chronic Lymphocytic Leukemia (2012) (2)
- PP-054 EFFICACY OF IDELALISIB IN CLL SUBPOPULATIONS HARBORING DEL(17P) AND OTHER ADVERSE PROGNOSTIC FACTORS: RESULTS FROM A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (2014) (2)
- Modulation of RNA splicing associated with Wnt signaling pathway using FD-895 and pladienolide B (2022) (2)
- Durable and Specific Inhibition of ROR1 Signaling Associates with Prolonged Progression Free Survival in Patients with Chronic Lymphocytic Leukemia Treated with Cirmtuzumab (2017) (2)
- ROR1 Expression Accelerates Leukemia Development in RORxTCL1 Transgenic Mice (2011) (2)
- Pro-Apoptotic Effects on CLL (Chronic Lymphocytic Leukemia) of ABT-737, a Novel Fully Synthetic Bcl-2/Bcl-XL Antagonist. (2004) (2)
- Immune Therapy for Chronic Lymphocytic Leukemia Induces the Antibody Response Against a Novel Tumor-Associated Antigen, the Orphan Tyrosine Kinase Receptor ROR1. (2005) (2)
- A Monoclonal Antibody Specifically Targeting CD44 Inhibits B-Cell Chronic Lymphocytic Leukemia Cell Survival In Vitro and In Vivo (2011) (2)
- Characteristics of Familial CLL Evaluated in the CLL Research Consortium Cohort (2008) (2)
- Expression of Sf3b1-K700E accelerates the Development of Chronic Lymphocytic Leukemia in a Del(13q) Murine Model (2020) (2)
- Obinutuzumab (Gazyva) and High-Dose Methylprednisolone (HDMP) Combination for Patients with Chronic Lymphocytic Leukemia (CLL) - a Phase Ib/II Study (2017) (2)
- Active Immune Gene Therapy Using ISF35: Responses Associated with Priming for Death Receptor-Induced Apoptosis and Sensitivity to Fludarabine in Patients with CLL and Del 17p (2008) (2)
- Addition of Rituximab Abrogates Ibrutinib-Induced Lymphocytosis and Promotes More Rapid Decrease in Absolute Lymphocyte Counts in Patients with Relapsed Chronic Lymphocytic Leukemia (2014) (2)
- Lenalidomide and Rituximab For The Treatment Of Patients With Relapsed Or Refractory Chronic Lymphocytic Leukemia: Results Of Planned Interim Analysis (2013) (2)
- ROR1 Negative Chronic Lymphocytic Leukemia (CLL) Have a Distinctive Gene Expression Signature and May Represent an Indolent-Disease Subtype (2015) (2)
- CAPTIVATE PRIMARY ANALYSIS OF FIRST‐LINE TREATMENT WITH FIXED‐DURATION IBRUTINIB PLUS VENETOCLAX FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LYMPHOMA (SLL) (2021) (2)
- Dynamics Changes in CCL3 and CCL4 Plasma Chemokine Levels in Patients with Chronic Lymhocytic Leukemia (CLL) Managed with Observation (2014) (2)
- Assessment of the Clonal Dynamics of Acquired Mutations in Patients (Pts) with Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Treated in the Randomized Phase 3 Murano Trial Supports Venetoclax-Rituximab (VenR) Fixed-Duration Combination Treatment (Tx) (2021) (2)
- LYMPHOID NEOPLASIA Trisomy 12 chronic lymphocytic leukemia cells exhibit upregulation of integrin signaling that is modulated by NOTCH 1 mutations (2014) (2)
- Prognostic testing patterns in CLL pts treated in U.S. practices from the Connect CLL registry. (2015) (2)
- UNFAVORABLE GENETICS IMPACT MRD RESPONSE TO VENETOCLAX+RITUXIMAB RETREATMENT IN RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (R/R CLL): PHASE 3 MURANO SUBSTUDY (2021) (2)
- Rituximab® and High Dose Methylprednisolone (HDMP) as a First Line Treatment for Patients with Chronic Lymphocytic Leukemia. (2005) (2)
- Genetic engineering strategies for hematologic malignancies. (2000) (2)
- Corrigendum to “Wnt5a Signaling in Normal and Cancer Stem Cells” (2017) (2)
- Correlation of clinical activity of lumiliximab in combination with FCR and ZAP 70 expression on B-cell chronic lymphocytic leukemia cells (2008) (2)
- Abstract 5485: Induction of proliferation sensitizes chronic lymphocytic leukemia cells to apoptosis mediated by the ATR inhibitor AZD6738 (2014) (2)
- Detection of Minimal Residual Disease in Chronic Lymphocytic Leukemia with Monoclonal Antibodies Specific for CD5, CD10, CD19, and ROR1. (2008) (2)
- Highly Specific Inhibitor for Syk Induces Chronic Lymphocytic Leukemia Cell Apoptosis (2011) (2)
- Chronic lymphocytic leukemia. (2007) (2)
- Correlations Between Ofatumumab Exposure and Treatment Outcomes for Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Frontline Ofatumumab, Fludarabine, and Cyclophosphamide Chemoimmunotherapy (2011) (2)
- Primary chronic lymphocytic leukemia (CLL) cells survival support from NLC and SDF-1a (CXCL-12) in vitro and the effect of lenalidomide (LEN) (2008) (2)
- Improvement in hematologic function, disease burden/symptoms with ibrutinib in older treatment-naive (TN) patients with chronic lymphocytic leukemia (CLL) in phase 3 RESONATE-2 (TM) (2016) (2)
- BAFF Accelerates Development of Chronic Lymphocytic Leukemia in TCL1 Transgenic Mice. (2007) (2)
- Targeting the CXCR4-CXCL12 Pathway Using an Anti-CXCR4 IgG1 Antibody (PF-06747143) in Chronic Lymphocytic Leukemia (2015) (2)
- X inactivation and immunocompetence in female carriers of the X-linked hyper-IgM syndrome. (1994) (2)
- ZAP-70 Enhances IgM Signaling in Chronic Lymphocytic Leukemia Cells Independent of Its Tyrosine Kinase Activity. (2006) (2)
- Agelastatin A (AgA), a Marine Sponge Derived Alkaloid, Inhibits Wnt/Beta-Catenin Signaling and Selectively Induces Apoptosis in Chronic Lymphocytic Leukemia Independently of p53 (2011) (2)
- Evaluation of oxaliplatin, fludarabine, cytarabine, and rituximab (OFAR) combination therapy in aggressive chronic lymphocytic leukemia (CLL) and Richter's syndrome (RS). (2010) (2)
- Associations of ofatumumab exposure and treatment outcomes in patients with untreated CLL receiving chemoimmunotherapy (2017) (1)
- Highly Efficient Gene-Transfer into Chronic Lymphocytic Leukemia Cells Using Adenovirus Type 35 Genetic Vectors. (2005) (1)
- Wnt5a Induces ROR1-Dependent Upregulation of MMP9 and Enhanced Invasiveness in Chronic Lymphocytic Leukemia (2019) (1)
- Impact of the Types and Relative Quantities of IGHV Gene Mutations in Predicting Prognosis of Patients With Chronic Lymphocytic Leukemia (2022) (1)
- Chronic Lymphocytic Leukemia Cells Can Induce Monocytes to Express High Levels of BAFF and Assume Properties of Nurselike Cells In Vitro. (2006) (1)
- Defining response criteria in CLL patients treated in clinical research trials Response (2010) (1)
- Cloning and Characterization of CLLD 6 , CLLD 7 , and CLLD 8 , Novel Candidate Genes for Leukemogenesis at Chromosome 13 q 14 , a Region Commonly Deleted in B-Cell Chronic Lymphocytic Leukemia 1 (2001) (1)
- Cirmtuzumab, a ROR1 Targeted Mab, Reverses Cancer Stemness, and Its Combination with Ibrutinib Is Safe and Effective: Planned Analysis of the Cirll Phase 1/2 Trial for CLL and MCL (2019) (1)
- B Cell Activating Factor and c-Myc Regulate the Progression of Chronic Lymphocytic Leukemia. (2009) (1)
- Inhibition of XIAP Enhances Specific Cytotoxic T Lymphocyte (CTL) Killing and CD20-Directed Antibody-Dependent Cellular Cytotoxicity of Chronic Lymphocytic Leukemia B Cells. (2004) (1)
- Final analysis from RESONATE: Six-year follow-up in patients (pts) with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) on ibrutinib. (2019) (1)
- PCN103 Variation in Health-Related Quality of Life by Age Among Patients With Chronic Lymphocytic Leukemia (2012) (1)
- Idelalisib Treatment Is Associated with Improved Cytopenias in Patients with Relapsed/Refractory iNHL and CLL (2015) (1)
- Nurse-like Cells Express High-Levels of Wnt5a, Which Induces ROR1-Dependent Signaling That Promotes Migration and Survival of Neoplastic Cells in Chronic Lymphocytic Leukemia (2017) (1)
- CD40-Activation of Chronic Lymphocytic Leukemia Cells Induces Latent Sensitivity to Fas/TRAIL-Mediated Apoptosis Via a P53-Independent, C-Abl-Dependent Pathway. (2004) (1)
- A Phase I Study of Immune Gene Therapy for Patients with CLL Using Intranodal Injection of ISF35, a Membrane-Stable CD40 Binding Protein. (2008) (1)
- Treatment Patterns and Outcomes of Patients with CLL Treated with Chemoimmuno- and Novel Agent-Based Therapy: A Multicenter Study (2018) (1)
- Progressive Epigenetic Programming during B Cell Maturation Is Reflected in a Continuum of Epigenetic Disease Phenotypes in Chronic Lymphocytic Leukemia (2015) (1)
- P669: FIXED-DURATION (FD) IBRUTINIB + VENETOCLAX FOR FIRST-LINE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LYMPHOMA (SLL): 3-YEAR FOLLOW-UP FROM THE PHASE 2 CAPTIVATE STUDY FD COHORT (2022) (1)
- Response: Letters regarding Blood. 2008;111:5446-5456 by Hanson et al and Mulligan et al (2009) (1)
- S107 FIVE-YEAR FOLLOW-UP OF PATIENTS RECEIVING IBRUTINIB FOR FIRST-LINE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (2019) (1)
- FCRL2 Expression Is Predictive of IgV H Mutation Status and Clinical Progression in Chronic Lymphocytic Leukemia. (2007) (1)
- Patterns of hepatitis B reactivation and liver test abnormalities in patients with chronic lymphocytic leukemia (CLL) treated with idelalisib plus an anti-CD20 antibody. (2016) (1)
- Protein kinase A and Epac (Exchange Protein Activated by cAMP) are Pro‐and Anti‐Apoptotic Mediators, respectively, in Chronic Lymphocytic Leukemia (2009) (1)
- A Phase 1 Clinical Trial of Cirmtuzumab, a First-in-Class ROR1 Inhibiting Antibody, for the Treatment of Patients with Relapsed or Refractory CLL: Interim Analysis (2016) (1)
- CCL3 and CCL4 Plasma Levels Correlate with Established Prognostic Markers in Chronic Lymphocytic Leukemia: Towards a Simple, ELISA-Based Assay for Risk Assessment. (2009) (1)
- Phase 2 Study of Acalabrutinib in Ibrutinib-Intolerant Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) (2019) (1)
- An International Multi-Center Study To Define the Application of Microarray-Based Gene Expression Profiling in the Diagnosis and Sub-Classification of Leukemia (MILE Study): Analysis of Completed Stage I with 2030 Patients Achieved a 95.4% Accuracy. (2007) (1)
- Gene therapy for cancer. (1993) (1)
- CXCL12 Enhances Survival of Chronic Lymphocytic Leukemia Cells Via a RAF-Dependent Pathway That Can Be Inhibited by Sorafenib (2010) (1)
- Correlation of Leukemia-Cell Birth Rate Measured by Heavy Water Labeling with Other Prognostic Markers in Early Stage Chronic Lymphocytic Leukemia. (2009) (1)
- A Phase I/II trial of CD3/CD28 activated T cells in patients with chronic lymphocytic leukemia (CLL). (2004) (1)
- Preclinical evaluation of anti-ROR1 CAR T cells employing a ROR1 binding SCFV derived from the clinical stage mab cirmtuzumab. (2020) (1)
- High-Level Expression of ROR1 Associates with Early Disease Progression in Patients with Chronic Lymphocytic Leukemia (2015) (1)
- CLL-Cell Proliferation Measured by In Vivo Deuterium Labeling in Early Stage Patients and Correlation with Other Prognostic Markers. (2007) (1)
- ICOS Is Induced by B Cell Receptor Signalling on Chronic Lymphocytic Leukemia B Cells. (2004) (1)
- The Target Genes and Prognostic Significance of Mir-150 in Chronic Lymphocytic Leukemia (2012) (1)
- heavy chain CDR3 expressed by chronic lymphocytic leukemia B cells is predicated on the Nonstochastic pairing of immunoglobulin heavy and light chains (2013) (1)
- Immunophenotypic characterization of relapsed chronic lymphocytic leukemia patients treated with lumiliximab in combination with FCR (2008) (1)
- MicroRNAs play a role in neoplasia (2007) (1)
- Mining the Microenvironment for Therapeutic Targets in Chronic Lymphocytic Leukemia (2021) (1)
- BAFF Support Survival of Chronic Lymphocytic Leukemia B Cells by a Pathway Independent of Stromal Derived Factor-1α. (2004) (1)
- Recurrent Gene Mutations and Clinical Outcome in the Context of Lenalidomide Treatment of Relapsed/Refractory CLL — Results from Multicenter Phase II Trial CLL-009 (2017) (1)
- A large fraction of trisomy 12, 17p−, and 11q− CLL cases carry unidentified microdeletions of miR-15a/16-1 (2022) (1)
- Wnt5a Induces ROR1 Dependent Tyrosine Phosphorylation of DOCK2, and Enhanced Activation of ERK to Promote Proliferation of CLL Cells (2018) (1)
- Interview: Chronic lymphocytic leukemia: treating an incurable disease (2013) (1)
- Single Cell Transcriptomic Characterization of the Immune Microenvironment in Naturally Progressing Chronic Lymphocytic Leukemia (CLL) (2018) (1)
- Expression of ROR1 in Chronic Lymphocytic Leukemia Cells Enhances Cells Survival by Wnt5a Signaling. (2007) (1)
- Wnt5a Induces Interleukin-6 Via a ROR1-Dependent Pathway in Chronic Lymphocytic Leukemia, Leading to Leukemia-Cell Activation of STAT3 (2017) (1)
- RANDOMIZED COMPARISON OF IBRUTINIB VERSUS OFATUMUMAB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA / SMALL LYMPHOCYTIC LYMPHOMA: RESULTS FROM THE PHASE III PCYC-1112 RESONATE((TM)) TRIAL (2014) (1)
- Circulating ofatumumab concentrations correlate with responseand progression-free survival in fludarabine-refractory chroniclymphocytic leukemia (2009) (1)
- Surface Antigens Identified by Antibody Microarray That Correlate with IgVH Mutational Status and ZAP70 Expression in CLL. (2005) (1)
- Human ROR1 Activates AKT and Accelerates Leukemia Cell Proliferation (2012) (1)
- Plasma Alemtuzumab Levels at End of Treatment Correlate with Response and Response Duration in Patients with CLL Receiving Treatment for Residual Disease. (2008) (1)
- Mitigation of tumor lysis syndrome (TLS) complications with venetoclax (VEN) in CLL. (2018) (1)
- Wnt5a Induces Association of ROR1 with Ca2+/Calmodulin-Dependent Protein Kinase II and ROR1-Dependent Calcium Influx in Chronic Lymphocytic Leukemia (2018) (1)
- Wnt5a Induces Association of ROR1 with 14-3-3ζ to Enhance Chemotaxis and Proliferation in Chronic Lymphocytic Leukemia (2016) (1)
- Erratum: Ofatumumab, a novel CD20 monoclonal antibody, is active in patients with fludarabine- and alemtuzumab-refractory or bulky fludarabine-refractory chronic lymphocytic leukemia irrespective of prior rituximab (Clinical lymphoma & Myeloma (2009) 9: 6 (E36) DOI: 10.3816/CLM.2009.n.098) (2010) (1)
- Ibrutinib plus Obinutuzumab as Frontline Therapy for Chronic Lymphocytic Leukemia Is Associated with a Lower Rate of Infusion-Related Reactions and with Sustained Remissions after Ibrutinib Discontinuation: A Single-Arm, Open-Label, Phase 1b/2 Clinical Trial NCT0231576 (2021) (1)
- SOHO State of the Art Updates and Next Questions: The Conundrum in Assessing the Therapy Response of Patients With Chronic Lymphocytic Leukemia. (2019) (1)
- Predicting Time to Initial Treatment in Early Stage CLL - Integration of Classical and Novel Prognostic Factors. (2008) (1)
- Rational Design and Real Time , In-Cell Detection of the Proapoptotic Activity of a Novel Compound Targeting Bcl-XL trials (2004) (1)
- Ad-ISF35 Intratumoral Administration Induces a Bystander Effect and Immune-Mediated Tumor Rejection with a Safe Vector Biodistribution and Toxicology Profile In a NHL Mouse Model. (2010) (1)
- Wnt5a Induces ROR1 to Interact Grb2 to Enhance Ras Activation in Chronic Lymphocytic Leukemia (2021) (1)
- Eradication of Minimal Residual Disease Using Alemtuzumab Consolidation After High-Dose Methyl-Prednisolone Plus Rituximab (HDMP-R) Is Safe, Effective and Induces Long Term Remission in Chronic Lymphocytic Leukemia (2011) (1)
- Abstract 343: Targeting SF3B1 mediated splicing control of Mcl-1 in chronic lymphocytic leukemia (2014) (1)
- Autoantibodies Against p53 Are Associated with p17 Deletions in CLL. (2007) (1)
- Expression of Lymphocyte Activation Gene 3 (LAG-3/CD223) by Chronic Lymphocytic Leukemia B Cells. (2005) (1)
- Selective Clearance of Chronic Lymphocytic Leukemia Cells in Vivo Following Treatment with UC99961, an Anti-ROR1 Monoclonal Antibody (2012) (1)
- Ofatumumab in combination with high-dose methylprednisolone for the treatment of patients with relapsed or refractory chronic lymphocytic leukemia. (2013) (1)
- Phase 1b/2 Study of Cirmtuzumab and Ibrutinib in Mantle Cell Lymphoma (MCL) or Chronic Lymphocytic Leukemia (CLL) (2021) (1)
- Cirmtuzumab Targets ROR1 to Inhibit Ibrutinib-Resistant, Wnt5a-Induced Rac1 Activation in Chronic Lymphocytic Leukemia (2016) (1)
- Heterogeneity and Evolution Of DNA Methylation In Chronic Lymphocytic Leukemia (2013) (1)
- Variation in Health-Related Quality of Life by ECOG Performance Status and Fatigue Among Patients with Chronic Lymphocytic Leukemia (2011) (1)
- Treatment Outcomes after Undetectable MRD with First-Line Ibrutinib (Ibr) Plus Venetoclax (Ven): Fixed Duration Treatment (Placebo) Versus Continued Ibr with up to 5 Years Median Follow-up in the CAPTIVATE Study (2022) (1)
- Wnt5a induces ROR1 to recruit cortactin to promote breast-cancer migration and metastasis (2019) (1)
- Abstract 1193: Treatment of breast cancer xenografts with paclitaxel enriches for cancer stem cells that can be targeted by a ROR1-specific antibody (2016) (1)
- Genome and Exome-Wide Studies Reveal Potential Predictive Efficacy Markers for Venetoclax and Rituximab (VenR) in Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL): Subgroup Analyses of the Murano Trial (2019) (1)
- A phase I/II study of Xcellerated T Cells in patients with chronic lymphocytic leukemia (2005) (1)
- Venetoclax Plus Rituximab can Achieve Durable Treatment-Free Remission in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (2016) (0)
- Targeting Chronic Lymphocytic Leukemia With DNA Nanoparticles (2013) (0)
- Immuno-gene therapy of non-hodgkin lymphoma using adenovirus encoding CD40 ligand (CD154) (2007) (0)
- IKZF3 Overexpression Phenocopies Gain-of-Function Mutation in Chronic Lymphocytic Leukemia (2020) (0)
- Chronic Lymphocytic Leukemia Cells May Become Less Dependent on Nurse-Like Cells during Later Stages of Disease. (2004) (0)
- Immune Gene Therapy for Patients with CLL Using Repeat Dose Intranodal Injection of Ad-ISF35, a Replication Incompetent Vector Expressing a Membrane-Stable CD40 Binding Protein. (2010) (0)
- leukemogenic selection high-risk disease and reflects antigen-driven, post-germinal-center Use of IGHV3-21 in chronic lymphocytic leukemia is associated with (2013) (0)
- Outcomes with ibrutinib by line of therapy and post-ibrutinib discontinuation in patients with CLL: phase 3 analysis (2019) (0)
- measurement of Cllu1 can monitor for minimal residual disease in patients with chronic lymphocytic leukemia after therapy : V92 (2010) (0)
- Ibrutinib for first-line treatment of chronic lymphocytic leukemia in patients aged >= 65 year of age : results with 5 years of follow-up for the RESONATE-2 study (2020) (0)
- FD-895 and Pladienolide B Modulate RNA Splicing Associated With Wnt Signaling Pathway (2021) (0)
- induction of Mcl-1 Protection of CLL B cells by a follicular dendritic cell line is dependent on (2013) (0)
- B-Cell Receptor Signaling Drives Glycolysis in Chronic Lymphocytic Leukemia Cells (2018) (0)
- Chemical Biology Strategy Reveals Cell Lineage- and Cell Differentiation-Specific Small Molecule Inhibitors of NF-κB. (2012) (0)
- Tecfidera Modulates Activation of Malignant B-Cells: Correlative Analysis from a Phase 1 Clinical Trial in Patients with Chronic Lymphocytic Leukemia (2018) (0)
- A Cyclopropane-Derived Stable Analog Of Fd-895 Induces Apoptosis and Inhibition Of mRNA Splicing In Lymphoma and Chronic Lymphocytic Leukemia: A Novel Therapeutic Approach (2013) (0)
- Gene Therapy for Neoplastic Hematology in Transplant Setting (2018) (0)
- **101 CCL3 (MIP-1 α) Plasma Levels and the Risk for Disease Progression in Chronic Lymphocytic Leukemia (CLL) (2011) (0)
- Short title: ZAP-70 Is A Conditional Hsp90-Client Protein In CLL (2013) (0)
- Proteogenomic Analysis of SF3B1 mut CLL Reveals Altered Protein Signaling Cascades and Metabolomic Pathways (2022) (0)
- MicroRNA Profiling in Patients with CLL B Cells Expressing the Unmutated IGHV1-69 Gene (2011) (0)
- Nonspecific Immune Activation Memory-Type B Cells That Respond to Lymphocytic Leukemia Generates Polyreactive Ig Expressed in Chronic Transgenic Expression of a Human (2004) (0)
- The Relative Dependency of Chronic Lymphocytic Leukemia (CLL) Cells on Nurselike Cells for in Vitro Survival Is Associated with Overall Survival in Previously Untreated CLL Patients (2008) (0)
- Generation of CD8+ T cell lines with specific cytotoxicity for autologous chronic lymphocytic leukemia B cells (2000) (0)
- Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation For Patients With Advanced Chronic Lymphocytic Leukemia (2010) (0)
- B Cell-Restricted Depletion of Dnmt3a Activates Notch Signaling and Causes Chronic Lymphocytic Leukemia (2021) (0)
- Influence of Mir-155 On B-Cell Receptor Signaling in Chronic Lymphocytic Leukemia. (2009) (0)
- A Phase I Study of Immune Gene Therapy for Patients with CLL Using a Membrane-Stable, Humanized CD154. (2007) (0)
- Race As a Determinant of Disease Biology and Outcomes in Chronic Lymphocytic Leukemia (2011) (0)
- Abstract P1-09-07: Breast cancer initiating cells express functional ROR1, which can be targeted by cirmtuzumab to potentially mitigate the risk of relapse after therapy (2018) (0)
- Intratumoral delivery of CD154 homolog (Ad-ISF35) induces tumor regression: analysis of vector biodistribution, persistence and gene expression (2012) (0)
- Genomic Analysis of Serial Chronic Lymphocytic Leukemia Samples Suggests That Epigenetic Changes, Rather Than Clonal Evolution, May Drive the Progression of This Leukemia (2012) (0)
- Genetic adjuvants for DNA immunization (1998) (0)
- Stereotypic IGHV3-21/IGLV3-21 Antibodies Expressed in High-Risk Chronic Lymphocytic Leukemia Bind Peptostreptococcus Magnus Protein L. (2007) (0)
- Differential Expression Profile of the Proteome and Transcriptome in Aggressive and Indolent Chronic Lymphocytic Leukemia. (2005) (0)
- In Vitro Propagation of Mesenchymal Stromal Cells From Marrow Aspirates of Patients with Chronic Lymphocytic Leukemia Is Dependent Upon Physiologic Oxygen Tension (2011) (0)
- dependent mechanism independent of functional p 53 WAF 1 / Cip 1 Lenalidomide inhibits the proliferation of CLL cells via a cereblon / p 21 (2014) (0)
- Early Events in the Clonal Evolution in Patients with Chronic Lymphocytic Leukemia Carrying TP53 Mutations and 17p Deletion (2008) (0)
- Efficient Gene Delivery to Chronic Lymphocytic Leukemia (CLL) Cells with Microbubbles Bearing ROR1 Antibody (2011) (0)
- Effect of a fully human anti-CD70 antibody on apoptosis and dephosphorylation of MAPK proteins in chronic lymphocytic leukemia (2008) (0)
- Epac1 is Up‐regulated in Chronic Lymphocytic Leukemic B‐Cells (2010) (0)
- Abstract 2650: Ags67e, an anti-cd37 monomethyl auristatin e antibody (mmae) drug conjugate as a potential therapeutic for non-hodgkin's lymphoma, chronic lymphocytic leukemia and acute myeloid leukemia (2014) (0)
- Fluorescence-Activated Cell Sorter and Monoclonal Antibodies: Complementary Tools in Immunodiagnosis and Immunotherapy (1985) (0)
- Abstract 3687: Wnt5a induces DOCK1 to complex with ROR1 and activate Rac1 leading to enhanced growth of breast cancer cells (2020) (0)
- malignancies B activation in hematologic κ Tcl1 interacts with Atm and enhances NF (2012) (0)
- Chronic Lymphocytic Leukemia Cells Have Increased Expression of Cyclic Nucleotide Phosphodiesterase 7B, Which May Serve as Disease-Specific Therapeutic Target. (2006) (0)
- A phase Ib clinical trial of Ad-ISF35-transduced autologous cells in combination with fludarabine, cyclophosphamide, rituximab (FCR) for patients with fludarabine-refractory and/or del(17p)/p53-defective chronic lymphocytic leukemia (CLL). (2011) (0)
- 5.55 Chronic Lymphocytic Leukemia Associated with Glomerular Disease: A Case Report of Successful Treatment with High-Dose Methyl-Prednisolone in combination with Rituximab Followed by Alemtuzumab (2011) (0)
- BAFF and APRIL Protect CLL B Cells from Apoptosis through Activation of NF-κB Canonical Pathway. (2005) (0)
- A cross reactive idiotype on rheumatoid factor is found in Sjogren's syndrome patients in different parts of the world (1989) (0)
- Robust integration of single-cell cytometry datasets (2021) (0)
- XPO1 mutations alter pathogenesis of chronic lymphocytic leukemia. (2021) (0)
- Abstract 4007: Evolutionary history of transformation from chronic lymphocytic leukemia to Richter’s syndrome (2022) (0)
- KDE Analysis in Chronic Lymphocytic Leukemia Patients with B Cells Expressing IGHV3-21 and Discordant Mutational Status between Heavy and Light Chain. (2007) (0)
- Heat Shock Protein 90 (Hsp90) Activity Status Is An Independent Prognostic Marker in Chronic Lymphocytic Leukemia (CLL) and Correlates with IgVH Mutational Status, ZAP-70 Expression and Time to First Treatment (2011) (0)
- Validation of CLL FISH Panel Scoring by Members of the Chronic Lymphocytic Leukemia Research Consortium. (2008) (0)
- Managing Adverse Events Associated With Monoclonal Antibodies and Other Alternative CLL Therapies (2011) (0)
- FIXED‐DURATION VENETOCLAX PLUS OBINUTUZUMAB IMPROVES PFS AND MINIMAL RESIDUAL DISEASE NEGATIVITY IN PATIENTS WITH PREVIOUSLY UNTREATED CLL AND COMORBIDITIES (2019) (0)
- 5.56 Ofatumumab in Combination with High-Dose Methylprednisolone as a Salvage Treatment for Heavily Pretreated or Refractory Patients with Chronic Lymphocytic Leukemia (2011) (0)
- Activation of AKT and Enhanced Resistance to Apoptosis Induced by Surface IgM Ligation in ZAP-70-Positive Chronic Lymphocytic Leukemia B Cells. (2005) (0)
- LYMPHOID NEOPLASIA Heat shock protein 70 regulates Tcl 1 expression in leukemia and lymphomas (2013) (0)
- pathways that associate with disease progression Subnetwork-based analysis of chronic lymphocytic leukemia identifies (2012) (0)
- Karyotype Results From CpG Oligodeoxynucleotide Stimulated Chronic Lymphocytic Leukemia (CLL) Cultures Are Consistent Among Laboratories: a CLL Research Consortium (CRC) Study. (2009) (0)
- Longitudinal Genomic Analyses In Chronic Lymphocytic Leukemia (CLL) Patients Reveal Clonal Relationship and Genomic Evolution In Disease Progression and After Therapy (2010) (0)
- LYMPHOID NEOPLASIA MicroRNA-155 in fl uences B-cell receptor signaling and associates with aggressive disease in chronic lymphocytic leukemia (2014) (0)
- Abstract #3613: Phase I study of direct intranodal injection of adenovirus encoding recombinant CD40-ligand (Ad-ISF35) in patients with chronic lymphocytic leukemia (2009) (0)
- Targeting Of Chronic Lymphocytic Leukemia B Cells With a Humanized Monoclonal Antibody Specific For ROR1 (2013) (0)
- lymphocytic leukemia cells lacking functional p53 CD154 induces p73 to overcome the resistance to apoptosis of chronic (2013) (0)
- MicroRNA-150 influences microenvironmental interactions andprognosis of B cell malignancies. (2015) (0)
- Plenary paper CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia (2000) (0)
- Ibrutinib vs chlorambucil: Immunophenotypic and quantitative impacts on circulating immune cells in chronic lymphocytic leukemia (CLL). (2017) (0)
- Abstract P2-01-10: Withdrawn (2019) (0)
- MicroRNA miR-150 contributes to the disease aggressiveness and regulation of B-cell receptor signalling (BCR) in CLL (2013) (0)
- A Bioinformatic Approach to CLL IGHV Sequence Analysis Identifies Extensive Ig Sequence Archetypes among BothMutated and Unmutated Sequences. (2005) (0)
- Study of VH3-21 in a Large Cohort of Chronic Lymphocytic Leukemia Patients Reveals Evidence for Antigen Selection and Confirms Its Predictive Value for Early Disease Progression. (2006) (0)
- Distinct evolutionary paths in chronic lymphocytic leukemia during resistance to graft-versus-leukemia (2020) (0)
- MicroRNA-150 influences microenvironmental interactions andprognosis of follicular lymphoma (2015) (0)
- Ad-ISF35-transduced autologous cells promote in vitro and in vivo chemosensitization in patients with 17p-/P53-defective chronic lymphocytic leukemia. (2009) (0)
- Variation in health-related quality of life (HRQOL) by line of therapy, age, and gender among patients with chronic lymphocytic leukemia. (2013) (0)
- Phase 3 Study of Ibrutinib versus Chlorambucil in Patients ≥65 Years with Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (2016) (0)
- Abstract 4051: MiR-181b expression levels decreases during the progression of the Chronic Lymphocytic Leukemia: a new potential prognostic tool (2010) (0)
- Epstein-Barr Virus-induced Human B-Cell Lymphomas in SCID Mice Reconstituted with Human Peripheral Blood Leukocytes1 (2006) (0)
- Expression vectors containing the genes for accessory molecule-ligand and its use for immunomodulation and treatment of malignant tumors and autoimmune diseases (1997) (0)
- Immunoglobulin gene expression in systemic rheumatic diseases. (1991) (0)
- Single Cell Profiling of B Cell Receptor Signaling and Apoptosis Networks in Chronic Lymphocytic Leukemia: Association with in Vitro Sensitivity to Fludarabine Monophosphate (F-ara-A). (2009) (0)
- Outcomes with Ibrutinib by Line of Therapy in Patients with CLL: Analyses from Phase 3 Data (2016) (0)
- Expression of ZAP-70 in Chronic Lymphocytic Leukemia Cells Enhances CD79b Phosphorylation Following Surface IgM Ligation. (2006) (0)
- Chemoimmunotherapy with ofatumumab, fludarabine andcyclophosphamide in previously untreated patients with chroniclymphocytic leukemia: a phase II international trial. (2010) (0)
- Chapter 5 Switching the Isotype of Monoclonal Antibodies (0)
- OP67 Immunotherapy of CLL (2007) (0)
- LYMPHOID NEOPLASIA miR-150 in fl uences B-cell receptor signaling in chronic lymphocytic leukemia by regulating expression of GAB1 and FOXP1 (2014) (0)
- Cirmtuzumab Consolidation for Treatment of Patients with Detectable CLL on Venetoclax (2020) (0)
- R-(−)-Gossypol (AT101) Binds to Bcl-2 Family Proteins and Induces Apoptosis in CLL. (2005) (0)
- LYMPHOID NEOPLASIA Translocation t ( 2 ; 11 ) in CLL cells results in CXCR 4 / MAML 2 fusion oncogene (2014) (0)
- Allele-Specific Loss Of The Mir-15a/16-1 Cluster Correlates With ZAP70 Expression In CLL Patients With 13q Deletion (2013) (0)
- Ethacrynic Acid Can Inhibit Wnt/β-Catenin Signaling and Induce Apoptosis in Chronic Lymphocytic Leukemia Cells. (2006) (0)
- CD137/4-1BB Is Inducibly Expressed On CLL B Cells through CD40 Signaling. (2009) (0)
- Ibrutinib Reduces Obinutuzumab-Gazyva Infusion Related Reactions (IRR) in Patients with Chronic Lymphocytic Leukemia (CLL) and It Is Associated with Changes on Plasma Cytokine Levels (2018) (0)
- ROR1 Is Expressed on the Surface of Non-Neoplastic Human B-Lymphocyte Precursors (Hematogones) and on a Subset of B Acute Lymphoblastic Leukemia (2010) (0)
- Lenalidomide Inhibits Proliferation of Chronic Lymphocytic Leukemia Cells in Vitro (2011) (0)
- Epstein-Barr Virus-induced Human B-Cell Lymphomas in SCID Mice Reconstituted with Human Peripheral Blood Leukocytes 1 (2006) (0)
- SKEWED AND UNSTABLE B-CELL REPERTOIRE IN SERIAL BLOOD SAMPLES OF HIV INFECTED PATIENTS. POTENTIAL ROLE IN THE INDUCTION OF AIDS-ASSOCIATED LYMPHOMA: 138 (1997) (0)
- Impact of cortactin in cancer progression on Wnt5a/ROR1 signaling pathway (2023) (0)
- Identification of Genotype-Specific Therapeutic Vulnerabilities By Comparative Dynamic BH3 Profiling Analysis of Human and Murine CLL (2019) (0)
- MicroRNA miR-150 contributes to regulation of B-cell receptro signaling (BCR) and disease aggressiveness in chronic lymphocytic leukemia (2013) (0)
- Chronic Lymphocytic Leukemia Cells Promote Increased BAFF Expression in Monocytes Partially through TNF-Alpha Leading to Increased CLL Cell Survival (2008) (0)
- Chimeric Antigen Receptor T Cells: Antigen Selection, CAR Development, and Data in Neoplastic Hematology (2018) (0)
- Methodes et compositions permettant de moduler l'apoptose (2005) (0)
- Nurse-like cells that support leukemic B cell survival are highly effective antigen presenting cells (2000) (0)
- A Complementary Role of High Throughput Sequencing and Multiparameter Cytometry for Minimal Residual Disease (MRD) Detection in Chronic Lymphocytic Leukemia (CLL):an European Research Initiative (ERIC) Study (2014) (0)
- Comparison of in Vitro Apoptotic Response of Chronic Lymphocytic Leukemia (CLL) Cells to Bcl-2 Antagonist ABT-737 and IAP Antagonist BV6. (2009) (0)
- Second Interim Analysis of a Phase 3 Study Evaluating Idelalisib and Rituximab for Relapsed Chronic Lymphocytic Leukemia (2014) (0)
- Elevated expression of PDE7B in Chronic Lymphocytic Leukemia (2006) (0)
- Supplemental Information Transcriptomic Characterization of SF 3 B 1 Mutation Reveals Its Pleiotropic Effects in Chronic Lymphocytic Leukemia (2016) (0)
- Methodes et compositions de modulation de l'apoptose (2005) (0)
- Preview : Published ahead of advance online publication EGR 2 mutations define a new clinically aggressive subgroup of chronic lymphocytic leukemia (2016) (0)
- Activation of NF-Kappa B-p62-NRF2 Signaling Supports the Survival of CLL Cells That Express High Levels of ROR1 (2018) (0)
- Inhibition of XIAP Renders Newly CD40-Activated Chronic Lymphocytic Leukemia Cells Sensitive to Fas (CD95) Mediated Apoptosis. (2004) (0)
- Abstract 206: Depletion of ovarian cancer initiating cells by a monoclonal antibody against ROR1 (2014) (0)
- Nurselike Cells in Chronic Lymphocytic Leukemia (CLL) Express Both BAFF and APRIL that Protect CLL B Cells from Spontaneous Apoptosis by Paracrine Manner. (2004) (0)
- Relative Prognostic Significance of ZAP-70 and IGHV1-69 Expression in Chronic Lymphocytic Leukemia, (2011) (0)
- Abstract 1789: Pre-clinical studies to advance anti-ROR1 CAR-T cell therapy for metastatic prostate cancer (2023) (0)
- Genetic variation in phosphodiesterase (PDE) 7B in chronic lymphocytic leukemia: overview of genetic variants of cyclic nucleotide PDEs in human disease (2013) (0)
- IDELALISIB PLUS AN ANTI-CD20 ANTIBODY IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WHO ARE HBV CORE ANTIBODY POSITIVE: SIMILAR PATTERNS OF LIVER TEST ABNORMALITIES (2016) (0)
- Therapeutic antibodies against the ROR-1 protein and procedures for their use. (2012) (0)
- Low Expression of ROR1 on Chronic Lymphocytic Leukemia Is Associated with Other Atypical Findings (2011) (0)
- Perspectives NewRoles for Rheumatoid Factor (2013) (0)
- The Kinase Inhibitor Sorafenib Can Disrupt the Survival Support Provided by the Microenvironment and Induce Apoptosis of Chronic Lymphocytic Leukemia Cells (2010) (0)
- Reasons for Initiation of First-Line Therapy and Early Outcomes for Patients (Pts) with Rai 0/1 Chronic Lymphocytic Leukemia (CLL): An Analysis of the Connect CLL® Cohort Study (2015) (0)
- CLLU1, a Novel Molecular Marker for Minimal Residual Disease Monitoring in Chronic Lymphocytic Leukemia (2008) (0)
- Ad-ISF35- Transduced Autologous Cells Promote In Vitro and In Vivo Chemosensitization to FCR and Durable Complete Responses In Patients with Del(17p)/P53 Defective Chronic Lymphocytic Leukemia. (2010) (0)
- Suppl 1 to Vol. 52: The Albert B. Sabin Vaccine Institute 4th Annual Colloquium on Cancer Vaccines and Immunotherapy, 6-10 March 2002, Walker's Cay, Abaco, Bahamas (2003) (0)
- Tcl-1 Inhibits Nuclear Export of TR3 and Is Highly Expressed in ZAP70-Positive CLL B-Cells. (2004) (0)
- Therapeutics , Targets , and Chemical Biology Targeting ROR 1 Inhibits Epithelial – Mesenchymal Transition and Metastasis (2013) (0)
- Immuno Genetic Analysis of Human Leu- 1 B Cell (1986) (0)
- Cirmtuzumab (Zilovertamab) Eliminates ROR1 Positive Leukemia Stem Cells By Blocking Niche Dependent ROR1/WNT5a Signaling (2022) (0)
- Fas-ligand ( CD 178 ) and TRAIL synergistically induce apoptosis of CD 40-activated chronic lymphocytic leukemia (2017) (0)
- Commentary Treatment of solid tumors with immunotoxins (2005) (0)
- 5.54 Ad-ISF35 Transduced Autologous Cells Induce Chemosensitization Activity and Complete Responses in Fludarabine-Refractory and/or del(17p)/p53-Defective Chronic Lymphocytic Leukemia Patients (2011) (0)
- Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma , Version 2 . 2019 CE (2019) (0)
- Five-Year Follow-Up After Ibrutinib Therapy for First-Line Treatment of Chronic Lymphocytic Leukemia (2019) (0)
- Abstract 975: MicroRNA-155 In chronic lymphocytic leukemia influences B-cell receptor signaling (2014) (0)
- High efficiency transduction of chronic lymphocytic leukemia with adenovirus type 35. (2006) (0)
- New expression vectors containing ancillary molekylligandgener and their use in the immunomodulation and the treatment of malignancies and autoimmune diseases (1997) (0)
- Abstract 3102: Venetoclax resistance associates with high-level expression of ROR1 and cancer stemness in chronic lymphocytic leukemia (2021) (0)
- chronic lymphocytic leukemia ZAP-70 enhances IgM signaling independent of its kinase activity in (2013) (0)
- AIDS-ASSOCIATED LYMPHOMA MAY BE COMPOSED OF POLYCLONAL B-CELLS, OR CONSIST OF A MONOCLONAL PROCESS WITHIN A SKEWED B-CELL POLYCLONAL BACKGROUND. (1998) (0)
- NF-κB-p62-NRF2 survival signaling is associated with high ROR1 expression in chronic lymphocytic leukemia (2020) (0)
- Abstract 3868: ROR1 is expressed in human breast cancer and associated with enhanced tumor-cell growth (2012) (0)
- MODULATEURS DE LA LIAISON ROR1-ROR2 (2016) (0)
- Recurrent Mutations in EGR2 Direct Specific Epigenetic Reconfiguration in Chronic Lymphocytic Leukemia (2018) (0)
- How Do Targeted Therapies Change the Management of Indolent Lymphomas? (2016) (0)
- response to therapy distinct molecular characteristics and does not indicate a suboptimal Prolonged lymphocytosis during ibrutinib therapy is associated with (2014) (0)
- Treatment of Chronic Lymphocytic Leukemia Patients with Lenalidomide Induces Down-Regulation of miR342-3p Associated with Over-Expression of Tumor Suppressor RASSF4, (2011) (0)
- Trisomy 12 CLL Cells Have High Surface Expression Of Integrins Involved In Lymphocyte Trafficking But This Does Not Translate Into Improved LFA-1-Mediated Motility (2013) (0)
- Abstract 3492: Wnt5a induces ROR1 to associate with DOCK1 and promote growth of breast cancer cells (2018) (0)
- Wnt5a Induces ROR1 to Complex with DOCK2 and Promote Proliferation of Chronic Lymphocytic Leukemia Cells (2017) (0)
- Neutrophil elastase is the 'histone H2A-specific protease' (2011) (0)
- Platinum-Based Compounds Induce Expression of p73 and Restores Drug- Sensitivity in p53 Dysfunctional Chronic Lymphocytic Leukemia (CLL) Cells. (2008) (0)
- Table of Contents (1986) (0)
- Cirmtuzumab Blocks Production of Proinflammatory Factors By Inhibiting Wnt5a/ROR1 Induced Activation of NF-Kappa B in Chronic Lymphocytic Leukemia (2018) (0)
- ZAP-70 Expressed in CLL Is an Hsp90 Client Protein and Its Level of Expression Can Be Downregulated by Specific Hsp90 Inhibitors. (2004) (0)
- Abstract P1-01-05: Wnt5a induces ROR1 to associate with cortactin, which undergoes tyrosine phosphorylation, and enhances migration of breast cancer cells (2018) (0)
- Tumor Debulking and Reduction in Risk of Tumor Lysis Syndrome with Single-Agent Ibrutinib (2017) (0)
- Interactome-Based Molecular Prognosis of Chronic Lymphocytic Leukemia (2008) (0)
- Response to Proinflammatory Cytokines Cell-Activating Factor of the TNF Family in Mesenchymal Origin Express Functional B Fibroblast-Like Synoviocytes of (2004) (0)
- Abstract 2368:miR-29-TRAF4axis is a novel regulator of CD40 signaling in malignant B cells (2021) (0)
- PS1151 PHASE 2 STUDY OF ACALABRUTINIB IN IBRUTINIB-INTOLERANT PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (2019) (0)
- Therapeutic antibodies to the rudder-1 protein and methods of use thereof (2012) (0)
- Common idiotypic specificities of anti-gat antibodies in various strains of mice. Abstr. (1978) (0)
- Expression of T Cell Co-Stimulator (ICOS) and Its Ligand and Disease Progression in B-Cell Chronic Lymphocytic Leukemia. (2005) (0)
- Phase 1 Study of Lumiliximabwith Detailed Pharmacokinetic and PharmacodynamicMeasurements in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (2007) (0)
- Expression of ZAP-70 in B Cell Chronic Lymphocytic Leukemia Is Associated with a Greater Capacity To Activate NFκB Following Ligation of Surface Immunoglobulin. (2004) (0)
- Inhibition Of Wnt Signaling In Chronic Lymphocytic Leukemia Has Synergistic Cytotoxicity With Ibrutinib (2013) (0)
- Analysis of the Serum Free Light Chain Ratio and Its Prognostic Value in a Cohort of Patients with Chronic Lymphocytic Leukemia. (2009) (0)
- Biased estimates of clonal evolution and subclonal heterogeneity can arise from PCR duplicates in deep sequencing experiments (2014) (0)
- Improved Outcome in Unrelated Donor Recipients After Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Advanced Relapse / Refractory Chronic Lymphocytic Leukemia (2011) (0)
- MalignanciesExpression in Normal Tissues and Lymphoid TNFR-Associated Factor Family Protein (2000) (0)
- Abstract #5486: Antigen displaying fluoromagnetic particles for drug assay in serum (2009) (0)
- Chronic Lymphocytic Leukemia Cells Produce a Soluble Factor(s) That Can Induce CD14+ Blood Mononuclear Cells To Assume Properties of Nurselike Cells In Vitro. (2007) (0)
- UNIVERSITY OF CALIFORNIA, SAN DIEGO 14-3-3zeta mediates the recruitment of ARHGEF2 onto ROR1 to facilitate Wnt5a- induced CLL proliferation/migration A Thesis submitted in partial satisfaction of the requirements for the degree Master of Science in Biology by (2016) (0)
- Comprar Williams manual de hematología 8Ed | Marshall Al Lichtman | 9786071510006 | MCGRAW HILL (2014) (0)
- DNA vaccines with rapid intracellular degradation are more effective for inducing CTL (1998) (0)
- Williams manual de hematología 8Ed (2014) (0)
- MiR-181b expression levels decrease during the progression of Chronic Lymphocytic Leukemia: a new potential prognostic tool (2010) (0)
- Increased Activity of Aldehyde Dehydrogenase, a Stem/Progenitor Cell Marker, in Chronic Lymphocytic Leukemia, (2011) (0)
- International, randomized phase 3 study results : Ibrutinib versus Chlorambucil in patients 65 years and older with treatment-naive CLL (RESONATE-2 (TM)) (2016) (0)
- Metastasis Mesenchymal Transition and − Targeting ROR 1 Inhibits Epithelial (2013) (0)
- Ad-ISF35-Transduced Autologous Cells Promote in Vitro and In Vivo Chemosensitization to FCR in Patients with Del(17p) / P53 Defective Chronic Lymphocytic Leukemia. (2009) (0)
- VX2 CARCINOMA IN THE 90s: AN ANIMAL MODEL FOR THE STUDY OF PERCUTANEOUS CANCER THERAPY (1993) (0)
- OP68 Gene therapy for patients with CLL (2007) (0)
- Title Pages / Table of Contents (2013) (0)
- CD154 (CD40-LIGAND) gene therapy for chronic lymphocytic leukemia leads to in vivo activation of the stat1 signaling pathway (2000) (0)
- Abstract 1514: An AC electrokinetic microarray device for isolation of cell circulating free nucleic acid from the blood of cancer patients (2014) (0)
- New expression vectors containing genes of accessory molecule ligands and their use for immunomodulation treatment of malignancies and autoimmune diseases. (1997) (0)
- Improved Outcome of CLL Patients with Leukemic Clones Expressing Mutated IGHV May Not Be Due to An Inability to Bind (auto)Antigen In Vivo (2010) (0)
- express virtually identical immunoglobulins Chronic lymphocytic leukemia B cells of more than 1% of patients (2013) (0)
- Patterns of Care of Aged Chronic Lymphocytic Leukemia Patients in the United States: Systematic Analysis of 457 Patients in the Connect CLL Registry (2014) (0)
- Leukemia B Cells Expressed by Chronic Lymphocytic Heavy Chains That Are Distinct From Those-Encoded Ig 51 p 1 Normal B Cells Express (2000) (0)
- Lenalidomide Inhibits Proliferation Of Chronic Lymphocytic Leukemia Cells Via a Cereblon/p21WAF1/Cip1-Dependent Mechanism (2013) (0)
- Chimeric ligand CD154 (2003) (0)
- Brief report Single nucleotide polymorphisms and inherited risk of chronic lymphocytic leukemia among African Americans (2012) (0)
- Abstract CT021: Assessing clinical and pharmacodynamic (PD) profiles of patients (pts) with chronic lymphocytic leukemia (CLL) on ianalumab (VAY736) + ibrutinib (2023) (0)
- Abstract CT028: Fixed-duration (FD) ibrutinib (Ibr) + venetoclax (Ven) for first-line treatment of chronic lymphocytic leukemia (CLL) in patients (pts) with high-risk features: phase 2 CAPTIVATE study (2022) (0)
- Variation in Health-Related Quality of Life by Age Among Patients with Chronic Lymphocytic Leukemia (2011) (0)
- Wnt5a Induces ROR1-Dependent NFkB Activation to Upregulate MMP9 and Enhance Invasiveness in Chronic Lymphocytic Leukemia (2022) (0)
- lymphomas Heat shock protein 70 regulates Tcl1 expression in leukemia and (2013) (0)
- Association of baseline ROR1 and ROR2 gene expression with clinical outcomes in the I-SPY2 neoadjuvant breast cancer trial. (2023) (0)
- Growth dynamics in naturally progressing chronic lymphocytic leukaemia (2019) (0)
- Abstract 5472: Targeting chronic lymphocytic leukemia cells with a humanized monoclonal antibody specific for CD44. (2013) (0)
- Utility of measurable residual disease for predicting treatment outcomes with BCR- and BCL2-Targeted therapies in patients with CLL (2022) (0)
- Targeting phosphodiesterase 7B and exchange protein directly activated by cAMP‐1 in chronic lymphocytic leukemia (2010) (0)
- Abstract LB255: Phase 1b trial of cirmtuzumab and paclitaxel for locally advanced, unresectable and metastatic breast cancer (2021) (0)
- Phase 1/2 study of zilovertamab and ibrutinib in mantle cell lymphoma (MCL) or chronic lymphocytic leukemia (CLL). (2022) (0)
- It is recommended that you download this PDF to your computer for furture reference. It spells out how CLL is treated clinically. (2008) (0)
- TCL1 Expression in Chronic Lymphocytic Leukemia Correlates with the Intensity of 11q Deletions and ZAP-70. (2007) (0)
- Chemotherapy-Based Regimes Increase Karyotype Complexity of Del(11q) CLL Cells and Impact the Response to Subsequent Ibrutinib Treatment (2022) (0)
- CLL-045: Long-Term Follow-up, Up to 7 Years, in the RESONATE-2 Study of First-Line Ibrutinib Treatment for Chronic Lymphocytic Leukemia (CLL) (2021) (0)
- S149 FIXED-DURATION VENETOCLAX PLUS OBINUTUZUMAB IMPROVES PROGRESSION-FREE SURVIVAL AND MINIMAL RESIDUAL DISEASE NEGATIVITY IN PATIENTS WITH PREVIOUSLY UNTREATED CLL AND COMORBIDITIES (2019) (0)
- LYMPHOID NEOPLASIA High-level ROR1 associates with accelerated disease progression in chronic lymphocytic leukemia (2016) (0)
- High Level Phosphatase Activity Revealed in Chronic Lymphocytic Leukemia Cells That Use Mutated Immunoglobulin Heavy Chain Variable Region Genes and Lack High-Level Expression of the Zeta-Associated Protein 70 (ZAP-70). (2007) (0)
- FIRST‐LINE TREATMENT WITH IBRUTINIB FOR PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): 7‐YEAR RESULTS FROM RESONATE‐2 (2021) (0)
- Obinutuzumab, High-Dose Methylprednisolone (HDMP), and Lenalidomide for the Treatment of Patients with Richter’s Syndrome (2022) (0)
- EFFECT OF SINGLE‐AGENT IBRUTINIB ON TUMOR DEBULKING AND REDUCTIONS IN TUMOR LYSIS SYNDROME (TLS) RISK IN PATIENTS (PTS) WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) (2017) (0)
- PS1123 IMPACT OF MAJOR GENOMIC ALTERATIONS ON OUTCOME OF RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS TREATED WITH VENETOCLAX PLUS RITUXIMAB IN THE PHASE 3 MURANO STUDY (2019) (0)
- Abstract CT166: Similar outcomes regardless of post-randomization treatment with ibrutinib or ibrutinib + venetoclax in the phase 2 CAPTIVATE study of first-line ibrutinib + venetoclax in CLL (2023) (0)
- Treatment Selection and Practice Patterns for the Management of High-Risk Chronic Lymphocytic Leukemia (CLL) in the US: An Analysis of the Impact of Risk Stratification on Treatment Selection from the Connect CLL® Registry (2015) (0)
- Fixed-duration (FD) ibrutinib (I) + venetoclax (V) for first-line (1L) treatment (tx) of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Three-year follow-up from the FD cohort of the phase 2 CAPTIVATE study. (2022) (0)
- CLL-418 Characteristics and Clinical Outcomes of Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Receiving Long-Term Ibrutinib Treatment in the RESONATE-2 Study. (2022) (0)
- FIVE‐YEAR FOLLOW‐UP OF FIRST‐LINE IBRUTINIB FOR TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA//SMALL LYMPHOCYTIC LYMPHOMA (2019) (0)
- Rituximab and High-Dose Methylprednisolone Debulking Prior to Venetoclax for Patients with Relapsed or Refractory CLL (2022) (0)
- Phase I-II Clinical Trial of Oxaliplatin, Fludarabine, Cytarabine, and Rituximab Therapy in Aggressive, Relapsed/Refractory Chronic Lymphocytic Leukemia or Richter’s Syndrome (2014) (0)
- PD04-10 PRE-CLINICAL STUDIES TO ADVANCE ZILOVERTAMAB-BASED ANTI-ROR1 DUAL SPECIFICITY CAR T-CELL THERAPY FOR METASTATIC PROSTATE CANCER. (2023) (0)
- The Relative Significance of ZAP -70 Promoter Methylation As a Prognostic Factor in Previously Untreated Chronic Lymphocytic Leukemia: Validation of Results Using a Second Large CLL Research Consortium (CRC) Patient Data Set (2012) (0)
- Characteristics and Clinical Outcomes of Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Receiving Ibrutinib for ≥5 Years in the RESONATE-2 Study (2023) (0)
- Structural Features of ROR1 Required for Complexing with ROR2 and Enhancing Chemokine-Induced Migration and Leukemia-Cell Proliferation, Which Can be Blocked By the Anti-ROR1 Mab Cirmtuzumab (UC-961) (2015) (0)
- ROR1 Expression Is Associated with Oncogenic Dedifferentiation in Chronic Lymphocytic Leukemia (2018) (0)
- Long-Term Analysis of Anti-CD20mab + HDMP for the Treatment of Patients with Chronic Lymphocytic Leukemia (2022) (0)
- Phase 1/2 Study of Zilovertamab and Ibrutinib in Mantle Cell Lymphoma (MCL), Chronic Lymphocytic Leukemia (CLL), or Marginal Zone Lymphoma (MZL) (2022) (0)
- Many People With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Benefit From Ibrutinib Treatment Up To 8 Years: A Plain Language Summary. (2023) (0)
- Analysis of Early Mortality of Chronic Lymphocytic Leukemia (CLL) Patients Treated in US Practices in the Connect CLL® Registry (2015) (0)
- 17. CytoGPS: A novel bioinformatics approach for high-throughput karyotype analysis (2018) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Thomas J Kipps?
Thomas J Kipps is affiliated with the following schools:
